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Carrier-Free High-Dose Dry-Powder Inhaler Formulation of  
Non-Steroidal Anti-Inflammatory Drugs 
Ashkan Khakparvar Yazdi, Ph.D. 
The University of Texas at Austin, 2016 
SUPERVISOR: Hugh D.C. Smyth 
Ibuprofen (IBU) is a non-steroidal anti-inflammatory agent (NSAID) is 
administered orally as tablets and suspensions. It is indicated for pain, fever, and other 
inflammatory conditions. More recently, a slower rate of respiratory decline is shown in 
cystic fibrosis (CF) patients on high, oral doses of IBU in comparison to placebo. The use 
of this treatment modality has not been well adopted or widespread due to high doses, 
side effects, contraindications, and black box warnings regarding the use of IBU. 
 Pulmonary delivery may be an attractive alternative to high-dose oral 
administration in CF since lungs are the desired targets for the anti-inflammatory and 
antibiotic activities of IBU. Typically with inhaled powders, a binary formulation of a 
drug with a carrier, such as lactose, significantly improves their performance; however, 
this strategy is not practical for the delivery of a large drug dose via a dry powder inhaler 
(DPI). Other inhalation devices such as nebulizers require significantly more time for 
drug delivery and metered dose inhalers may be incapable of metering sufficiently large 
drug doses. Therefore, carrier-free DPIs have been explored for large drug dose delivery. 
IBU exists as the stable polymorph I (in its acicular crystal habit), or as the less 
stable polymorph II. Low melting point (75.85°C), water solubility, and crystal habit of 
ibuprofen make its processing challenging. A novel air-jet milled carrier-free formulation 
of IBU was developed using the design of experiment approach, which possessed 
superior flowability, in-vitro aerodynamic performance determined by Next Generation 
Impactor. Furthermore, the developed formulation possessed at least one-year stability at 
room temperature in the desiccator under vacuum. 
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Objective: To provide a survey of common particle engineering technologies used for the 
preparation of nanoparticles and microparticles, to evaluate the effect of these 
technologies on the properties of end-product, and to discuss the critical properties of 
compounds, which dictates the type technologies to be utilized to process a specific 
compound. 
Background: Microparticles and nanoparticles are intended to increase the 
bioavailability of compounds with low water solubility. Furthermore, microparticles are 
utilized to deliver to a specific cite such as lungs. Finally, microparticles and 
nanoparticles are of great importance in preparation of stable suspensions.  
Results: From the top-down and bottom-up particle engineering techniques, the top-down 
particle engineering techniques, namely different milling techniques, have been utilized 
the most to produce nanoparticles and microparticles. The most common bottom-up 
process in particle engineering is spray drying, which allows for the production 
amorphous and crystalline particles with different morphologies. The popularities of 
these techniques lie in the ability to scale-up from laboratory to commercial. Particle 
engineering technologies may influence the phase of final product through 
mechanochemical transformation and induce the transition of a crystalline to an 
amorphous phase or vice-versa. Finally, physicochemical properties of drugs such 
melting point and crystal lattice strength dictate the particle engineering technologies, 
which can be utilized to produce nanoparticles and microparticles.  
	 3	
Conclusion: There have been tremendous advances in the development of particle 
engineering technologies. Mechanochemical transformation constitutes the primary 
influence of these technologies on the properties of the final product. Physicochemical 
properties of starting material should dictate the type of processing methods in 





The primary purpose of the transformation of active pharmaceutical ingredients 
(APIs) into a fine powder is to enhance their bioavailability through an increase in the 
dissolution rate. Other purposes for this transformation are to target the formulation to 
respiratory route and to formulate stable suspensions. One, or more particle engineering 
steps are usually required during formulation development since almost all formulations 
start from a solid active pharmaceutical ingredient (API) directly from a manufacturer as 
a bulk material, or there is a distinct downstream particle-engineering step.  
Particle engineering methods utilized for the production of fine powders include 
bottom-up and top-down processes. Bottom-up processes include controlled 
crystallization, spray chilling, melt-emulsification, spray drying, and the rapid expansion 
of supercritical solutions. Top-down processes, also known as comminution methods 
include dry-milling, wet-milling, and high-pressure homogenization. The processing 
method selection criteria include the desired particle size range, as well as 
physicochemical properties of the material including polymorphism, solubility, and 
stability.  
In this review, an overview of different particle engineering techniques will be 
provided. Furthermore, strengths and limitations of each method will be discussed. 
Finally, API properties affecting decision making for the use of one method over another 
method will be discussed. 
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1.1. Dissolution rate 
As of 2006, about 40% of top 200 drugs sold in the United States were considered 
to be practically insoluble in water (Takagi et al., 2006) and significantly higher 
percentage of drug candidates in development belong to this category and present 
significant challenges for drug development. Specifically, drug candidates, belonging to 
the biopharmaceutic classification system (BCS) class II, possess high membrane 
permeability and low aqueous solubility. Therefore, their bioavailability will suffer from 
erratic or incomplete absorption due to poor aqueous solubility (Amidon et al., 1995). 
One approach for increasing the bioavailability these drug candidates is to increase their 
dissolution rate.  
According to Nernst-Brunner equation (Equation 1), drug dissolution rate (dC/dt) 
increases with an increase in drug surface area (S), which can be achieved through 
particle size reduction (Dokoumetzidis and Macheras, 2006). Other variables in this 
equation are drug diffusion coefficient (D), drug concentration surrounding the drug 
particles in the diffusion layer (Cs), drug concentration in bulk dissolution media (C), the 
volume of the dissolution medium (V), and diffusion layer thickness (h). 
 !"!" =
! ! 
! ! (!! − !) Equation 1 
Furthermore, saturation solubility is a function of particle size, and their 
relationship is explained by the Ostwald-Freundlich equation (Equation 2), where smaller 
particle sizes are associated with an increase in the saturation solubility (Simonell.ap et 
al., 1970). In this equation, Cs,r and Cs,∞ are the solubilities for a particle with a radius of r 
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and a very large particle; γ is the interfacial tension; Vm is the molar volume; R is the gas 
constant; and T is the absolute temperature. 
 !" !!,!!!,! =  
! ! !!
!"#  Equation 2 
1.2. Suspensions 
Particle size significantly affects the physical stability of a suspension. 
Specifically, sedimentation velocity for spherical particles in a suspension is governed by 
the Stokes’ law (Equation 3).  
 ! = !!!(!!!!!)!!!  Equation 3 
In this equation, r is the radius of particles, ρ1 and ρ2 are densities of the dispersed 
phase and dispersion medium, g is the gravitational acceleration and η is the Newtonian 
viscosity of the dispersion medium. According to the Stokes’ law, suspensions with 
smaller particle size are expected to have a slower sedimentation velocity. Furthermore, 
higher interparticulate interactions in these suspensions due to the increased surface area 
may lead to a favorable increase in the viscosity and the stability of the suspension. 
Conversely, suspensions with smaller particles may be prone to caking if they are not 
flocculated (Kulshreshtha et al., 2009). 
A mono-dispersed particle size distributions are preferred over poly-dispersed 
particle size distribution for the development of stable suspension systems as they will be 
associated with a more uniform sedimentation velocity. Additionally, flocculated 
suspensions from mono-dispersed distributions will be less dense than ones from poly-
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dispersed distributions where small particles fill voids between larger particles. Finally, 
poly-dispersed distributions suffer to a greater extent from Oswald ripening where 
temperature fluctuations lead to the dissolution of smaller particles and crystal growth on 
larger particles.  
1.3. Pulmonary drug delivery 
The pulmonary route represents an alternative to the oral and the parenteral route 
of delivery for local and systemic delivery small molecules but more specifically protein 
and peptide drugs (Patton and Platz, 1992). Drug physicochemical properties 
administered via inhalation vary significantly: logP [–2 (albuterol sulfate) to 5 
(fluticasone propionate)], solubility [0.1 µg/mL (fluticasone propionate) to 250 mg/mL 
(albuterol sulfate)]. Lung fluid is composed of water mainly (96%), salts, phospholipids, 
proteins, and mucin with pH of about 6.6 in healthy individuals (Olsson et al., 2011). 
Moreover, the total liquid volume available for dissolution is approximately 10 – 30 mL 
with 5 – 10 µm thickness in conducting airways and much lower thickness of 0.01 – 0.08 
µm with the maximum of several microns thick in some regions in the alveoli (John S., 
1996). The large absorptive surface area of approximately 100 m2 and superior blood 
perfusion enable the rapid absorption and onset of action of drugs (Labiris and Dolovich, 
2003). Furthermore, systemic absorption from lungs is associated with minimal hepatic 
first-pass metabolism (Patton et al., 2004). Alternatively, local lung delivery with 
minimal systemic absorption is associated with therapeutic local concentration and 
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minimal drug distributions in other tissues. Tissue-selective distribution limits side 
effects and increases therapeutic indices. 
Respiratory system structural design, its primary protective mechanism, prevents 
alveoli deposition of all particles except particles with a narrow aerodynamic diameter 
size range between 0.5 to 5 µm. Successful deep lung deposition for dry powder inhaler 
(DPI) formulations, is strongly correlated to the percentage of particles with an 
aerodynamic diameter less than 3 µm and particles and particles larger than this size are 
deposited in the upper airways (Newman and Chan, 2008). As depicted in Equation 1, for 
spherical, solid particles, the aerodynamic diameter is equal to the geometric diameter 
(Deq) where particle density (ρp) is equal to unit density (ρo) and the dynamic shape factor 
(χ) is equal to one (Telko and Hickey, 2005).  
 !!" =  !!"  !!!! ! (Equation 4)  
Pulmonary formulations are delivered to the lungs via three distinct classes of 
devices including dry powder inhalers (DPIs), pressurized meter dose inhalers (pMDIs), 
and nebulizers (Frijlink and de Boer, 2005). Aerosol deposition in the airways is a 
function of the physical structures of the airways, the physics of particle motion, and 
airflow dynamics. If inhaled particles are not exhaled due to the particle size less than 0.5 
µm, they may deposit in the various regions of the respiratory system by the action of 
five different deposition mechanisms: interception, inertial impaction, diffusion, 
gravitational settling, and electrostatic attraction (Hinds, 2012).  
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2. Particle engineering technologies 
As it was previously discussed, particle-engineering technologies are utilized to 
produce microparticles and nanoparticles to enable route specific delivery and to improve 
saturation solubility, dissolution rate, and formulation stability. 
2.1. Top-down approaches 
Top-down approaches also known as destructive approaches are the most widely 
used technologies to produce microparticles and nanoparticles. Milling methods can be 
classified as shear milling, compression milling, and impaction milling where relatively 
larger particles are produced by shear milling and the smallest particles are produced by 
impact milling. 
2.1.1. Milling  
Various milling techniques are capable of producing particles with different 
particle sizes ranging from very fine to colloidal particles (Zheng, 2009). Table 1.1 
depicts the various dry and wet milling techniques and size ranges associated with them. 
Milling methods can be divided into dry-milling where the milling media is gas, or wet-
milling where the milling media is liquid methods. Particle-size reduction occurs by 
compression, impaction, and attrition through collision of particles with the surfaces of 
the equipment as well as with each other (Clement and Purutyan, 2002; Friedrich, 2001). 
Furthermore, during the wet-milling process, the liquid milling media exhibits shearing 
and cavitational forces contributing to the particle-size reduction (Sharma et al., 2009). 
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Regardless of milling technique, particle density and residence time of particles can 
affect both the milling rate and its efficiency.  
2.1.1.1. Ball milling 
Ball mill is composed of a rotating vessel filled partially with balls where 
comminution is caused by attrition and impaction. In a wet ball mall, the vessel is filled 
three-quarters way with pearl balls along with a suspension of the drug with stabilizers 
and in contrast to the high-pressure homogenization, micronized drug are obtained using 
a lower energy input. Most notably, a wet ball mill is branded as NanoCrystal® 
technology, and the API for processing is suspended in the dispersion medium. 
Suspensions for oral and parenteral use are stabilized using surfactants and there no 
requirement for subsequent drying due to stability concerns.  
2.1.1.2. Fluid energy milling 
Fluid energy mills can be classified into two general categories of loop/spiral 
mills also known as air-jet mills and attrition mills also known as fluidized bed jet mill. 
This classification is based on whether the jets of grinding gas are introduced tangentially 
in the direction of airflow, or are impinging at a central point where maximal particle-
particle collisions are expected to result in breakage. Milling pressure is between 3 and 
10 bar corresponding to 43.5 and 145 psi (Rasenack and Müller, 2004). Fluidized bed jet 
mills can mill harder materials in comparison with spiral jet mills. Furthermore, a 
classifier prevents the premature departure of unmilled solid from the milling chamber in 
the fluidized bed jet-mills as opposed to spiral jet mills. For fluidized bed jet mills with a 
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rotatory classifier, specific surface area is a function of grinding pressure and the speed of 
rotation for the classifier (Nakach et al., 2004). Spiral jet mills benefit from an internal 
classifier where larger particles stay on the periphery of the grinding chamber and finer 
particles, entrained in the air current, exit the grinding chamber. Fine particles may be 
fractionated further using a cyclone separator at a specific particle cutoff size.  
2.1.1.3. Cryogenic milling 
Two different processes involving cryogenic conditions constitute cryogenic 
milling or cryomilling. The first process is a ball milling, where the cryogenic liquid is 
added to the grinding chamber and material is in direct contact with the cryogenic liquid. 
The second process involves cooling down the grinding chamber where material is not in 
direct contact with the cryogenic liquid. In cryomilling, particle size reduction occurs at 
controlled low temperatures where material brittleness favors particle fracture upon 
compression, impaction, and attrition (Witkin and Lavernia, 2006). One significant 
advantage of this method is to process heat-sensitive materials; however, particle 
aggregation induced by moisture condensation during sample recovery and cryogenic 
liquid removal is a major drawback (Fisher, 2013). Other drawbacks includes 
amorphization with prolonged duration of milling (Macfhionnghaile et al., 2014).  
2.1.1.4. Sonofragmentation 
Sonofragmentation is the process during which ultrasound is used to decrease 
particle size. Ultrasound waves possess alternating periods of compression and expansion 
while propagating through a liquid. Its chemical and physical effects on materials arise 
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from acoustic cavitation, the formation, growth, and implosive collapse of bubbles in the 
liquid during ultrasound expansion periods. The implosive collapse of bubbles creates 
shockwaves with velocities of ~4000 m/s and amplitudes of 106 KPa (Suslick, 1989). 
Isolated sub-micron reactors are predicted to have local temperatures of ~5000 K, 
pressures of ~ 105 KPa, and heating and cooling rates above 109 K/s and are responsible 
for sonochemistry (Suslick, 1990). Zeiger and Suslick ruled out interparticle, particle-
horn, and particle-wall collisions as potential mechanisms for sonofragmentation and 
proposed particle-shockwave interactions as the mechanism for this process (Zeiger and 
Suslick, 2011). Pérez-Maqueda et al. processed down talc to submicron particles using 
sonofragmentation and observed delamination and lateral particle size reduction followed 
by agglomeration with further particle size reduction when ultrasound was applied for 
longer than 40 h (Pérez-Maqueda et al., 2005). 
2.1.2. High-pressure homogenization 
Homogenization is a particle-size reduction process for the preparation of 
emulsions; however, it has been utilized to reduce the particle size of suspensions. 
Through this process, the polydispersity of sample particle size distribution is decreased. 
The sample is “homogenized” due to fluidic turbulence, cavitation, and shear. The type of 
homogenizer (i.e. piston-gap vs. jet-stream) along with the physical properties of the bulk 




2.1.2.1. Piston-gap homogenization 
A piston-gap homogenizer forces a macrosuspension consisting of a drug 
dispersed in an aqueous surfactant solution through a 5 to 20 µm gap using a piston under 
pressures up to 4000 bars and is also known as DissoCubesTM technology (Muller et al., 
1999). An increase in the dynamic pressure caused by a high streaming velocity in the 
gap is compensated by a decrease in the static pressure below the vapor pressure of water, 
which causes it to boil and to form gas bubbles. Cavitation occurs with the collapse of 
gas bubbles immediately after the gap, creates high power shockwaves, and results in 
particle size reduction (Shegokar and Mueller, 2010).  
Nanopure® technology is a piston-gap homogenizer variant where non-aqueous 
liquids with low vapor pressure (i.e. oils, polyethylene glycol) are used instead of water. 
Due to the absence of cavitation with low vapor pressure, hydrodynamic shear forces and 
drug particle collisions are responsible for particle size reduction. 
2.1.2.2. Jet-stream homogenization 
Also known as a microfluidizer, a jet-stream homogenizer operates based on the 
jet stream principle where two fluid streams collide under pressures up to 1700 bars in a 
Y-type or Z-type chamber. Forces of shear, impaction, and cavitation in the collision 
chamber are responsible for particle size reduction and surfactants are added to stabilize 
these particles. Strydom et al. prepared nanoparticle complexes of sulfadiazine, silver, 
and poly(amidoamine) dendrimers using jet-stream homogenization technique to create a 
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uniform distribution of these nanoparticles with increasing the number of process cycles 
(Strydom et al., 2013).  
2.2. Bottom-up approaches  
2.2.1. Spray-drying 
Spray-drying is a one-step, scalable, constructive particle engineering process as 
opposed to milling, a destructive particle engineering process, for the production of drug 
aerosol particles (Xu and Hickey, 2011). The first patent on spray-drying was filed in 
1872 by Peroy, SR (Drying, 1872). In the spray-drying method, a solution, a coarse 
suspension, fine suspension, a colloidal dispersion (e.g. emulsion, liposomes, etc.), or 
paste of an active pharmaceutical ingredients (API) alone, or with other excipients are 
atomized and are dried by contact with hot air (Mujumdar, 2006). Atomization methods 
used include centrifugal (e.g. spinning disk), kinetic (e.g. pneumatic), high pressure, 
ultrasonic, electrostatic, and effervescent. Separation occurs via the use of a cyclone, 
electrostatic precipitator, or a bag filter (Van Oort and Sacchetti, 2007). 
Advantages of spray drying for particle engineering include processing of 
materials, which are heat labile and have low aqueous solubility.  Furthermore, it is a 
scalable continuous processing method, which allows for a high degree of tunability for 
product properties (e.g. particle size, size distribution, particle shape, density, and 
macroscopic powder properties such as bulk density, flowability, and dispersibility). 
Finally, process optimizations allow for the production of aerosolizable powder would 
not require post-processing modification such as lyophilization (Van Oort and Sacchetti, 
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2007). Disadvantages of spray drying include low material bulk desnsities, liquid vehicle 
dependent operation, and the requirement for pumpable feed material (Mujumdar, 2006). 
2.2.2. Cryogenic technologies 
In these methods, cryogenic liquid most commonly liquid nitrogen is utilized to 
improve the solubility and dissolution of poorly water-soluble drugs by freezing a feed 
formulation with subsequent solvent removal (Yang et al., 2012). 
2.2.2.1. Spray-freeze drying 
As oppose to spray drying with atomization and drying steps, spray-freeze drying 
(SFD) consists of three steps: atomization, freezing, and sublimation. The atomization 
step is conducted on a feed solution, emulsion, or suspension of a drug alone or in 
combination with other excipients. The freezing step involves the freezing of the 
atomized droplets using the cryogenic liquid. The final step of sublimation involves the 
solvent removal from the frozen particle. The final product usually yields an amorphous 
powder. This method was first used to process proteins and peptides, because unlike 
spray drying techniques, no heat is required, which prevents proteins and peptides 
denaturation (Benson and Ellis, 1948). It is only in the early 1990s that SFD started to be 
used by pharmaceutical industries to prepare amorphous forms of poorly water-soluble 
drugs (Mumenthaler and Leuenberger, 1991; Zijlstra et al., 2007).  
2.2.2.2. Spray freezing into liquid 
Developed and patented by Williams, et al. (Williams et al., 2005) and 
commercialized by Dow Chemical Company, and Enavail LLC, spray freezing into 
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liquid (SFL) involves steps akin to spray-freeze drying; however, the atomization process 
occurs in the cryogenic liquid were the atomized droplets are frozen upon contact with 
the cryogenic liquid resulting in better stability profile (Yu et al., 2006). The powders 
processed with the SFL technology are micron size nanostructures with an amorphous 
morphology, high porosity, hence, they possess high surface area (Hu et al., 2004a), 
which improve the wettability and enhance dissolution properties of the poorly water-
soluble drugs processed by SFL (Hu et al., 2004b).  
2.2.2.3. Thin film freezing 
Similarly to the SFL and the SFD technologies, the thin film freezing (TFF) 
process starts with a feed solution containing the drug alone, or in combination with other 
pharmaceutical excipients. The feed solution is frozen dropwise on a pre-cooled (below 
the lowest freezing temperature of the solvent used to dissolve the drug and the 
excipients) rotating cryogenic substrate. Similar to the SFD and SFL technologies, the 
solvents are removed by freeze-drying to obtain dry powders (Beinborn et al., 2012). This 
process is utilized to created micro-aggregates containing primary nanoparticle structures 
of amorphous or crystalline materials and to improve the dissolution of poorly water-
soluble drugs by increasing the specific surface area of the particles and modifying their 
crystal structure (Overhoff et al., 2007). The cooling rate of the TFF process (~102 K/s) 
produces rapid nucleation and significantly prevents particle growth, as the particles are 
immobilized in the frozen state. The size of the primary structures is controlled by the 
process parameters and the formulation composition: the solvent composition, the 
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percentage of dissolved solids in the feed solution and the temperature of the cryogenic 
surface (Beinborn et al., 2012; Engstrom et al., 2008).  
2.2.3. Controlled precipitation technologies 
Controlled crystallization or precipitation processes allow for the particle size 
control of APIs and production of narrowly distributed particle sizes (Am Ende and 
Brenek, 2004). Crystallization driving force is supersaturation, which is achieved with 
thermal swing and antisolvent addition and is followed by nucleation and crystal growth 
(Mullin, 2001). Alternatively, if the amorphous phase growth rate is greater than the 
crystalline phase growth rate, the resulting phase will be amorphous. A critical step to 
control the crystal particle size distribution is to stabilize the particles using surface-
active agents. 
2.2.3.1. Solvent antisolvent precipitation 
During this bottom-up particle engineering method, nanoparticles and 
microparticles are formed with the addition of an antisolvent to a drug solution where the 
solvent and the antisolvent are miscible. The addition of the miscible antisolvent 
decreases the saturation solubility of the drug in solution and results in supersaturation, 
which is followed by nucleation and precipitation. Generated particles are crystalline; 
however, there have been reports for the generation of amorphous particles using 
solvent-antisolvent precipitation technique. Viçosa et al. generated amorphous rifampicin 
nanoparticles from a room temperature ionic liquid (RTIL) with a phosphate buffer as 
antisolvent (Viçosa et al., 2012). RTIL are organic salts, which are liquid at room 
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temperature. Particle size control is the primary challenge regarding this method as a high 
concentration of surfactants is required to control it. 
2.2.3.2. Evaporative precipitation into aqueous solution (EPAS) 
EPAS process allows for the formation of submicron particles coated with 
hydrophilic stabilizer. During this process, the drug is dissolved in an organic solvent and 
is atomized into an aqueous solution of hydrophilic stabilizer (Chen et al., 2002). During 
the atomization step, the organic solvent evaporates, supersaturation is reached, and 
particle formation ensues. Generated particles using EPAS method have been reported to 
be amorphous since amorphous phase growth rate exceeds the crystalline phase growth 
rate, and the hydrophilic stabilizer is thought to prevent crystallization (De Yoreo and 
Vekilov, 2003). 
2.2.3.3. Emulsion templates 
Emulsion templates are a group of particle engineering techniques including the 
emulsion solvent evaporation method, which involves the formation of stable emulsions 
followed by solvent evaporation. Emulsions may consist of oil-in-water, water-in-oil-in-
water, or water-in-oil. The utilized solvent evaporation techniques include: vacuum 
drying, lyophilization, spray drying, one of the cryogenic technologies and followed by 
sublimation. The formation of stable emulsions is the key step in particle engineering 
using this technology. Emulsions are thermodynamically unstable system since they 
possess a positive free energy of emulsion formation (ΔG) due their large interfacial 
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energy (λΔA) in comparison with the entropy of droplet formation (ΔSi) as it is depicted 
in Equation 5.  
 ∆G =  λ ∆A− T ∆S Equation 5 
2.2.3.4. Sonocrystallization 
As opposed to passive crystallization technologies, which were previously 
discussed, sonocrystallization utilizes ultrasound during the crystallization process. 
Independent of supersaturation level during the crystallization process, ultrasound 
induces nucleation and decreases induction time, the time elapsed from supersaturation to 
the formation and detection of crystals (Sander et al., 2014). Ultrasonic shockwaves 
increase the nucleation rate, and cavitation bubbles increase the number of nucleation 
sites thereby sonocrystallization yield particles with narrow size distribution in 
comparison with passive crystallization techniques (Nalajala and Moholkar, 2011). 
2.2.4. Supercritical fluid technologies 
Supercritical fluid (SCF) is a fluid that was compressed beyond its critical 
pressure (Pc) or was heated above its critical temperature (Tc). Small changes in pressure 
lead to significant changes in SCF densities leading to significant variations in 
diffusivity, viscosity, as well as the solubility of other solvents and small solutes. 
Furthermore, SCFs’ diffusivities are ~100 times greater, and their viscosities are ~100 
times lower than that for liquids, and they lead to rapid supersaturation and nucleation 
and favor the production of small particles. With a relatively low Tc and an average Pc 
supercritical carbon dioxide (CO2) is the most prevalent SCF since it is inexpensive, 
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nonflammable, and nontoxic. Depending on the solubility of API in SCF, different 
methods have been developed for particle engineering. 
2.2.4.1. Gas antisolvent precipitation (GAS) 
Gas antisolvent precipitation method is based on a low solubility of API in the 
SCF, and the miscibility of SCF and the API solvent. Particles are produced through the 
addition of SCF to a solution of API in the solvent, where the solubility strength of 
solvent for the API is decreased, and the supersaturation is followed by the nucleation 
and precipitation (Martin and Cocero, 2008). Formulations of API and excipients are 
prepared when initially the API and excipients are dissolved in the solvent and SCF is the 
antisolvent for all components. Key process parameters include pressure and temperature 
of precipitation chamber, solvent selection, and SCF addition rate (Muhrer et al., 2003). 
Both crystalline and amorphous particles have been produced utilizing the GAS method 
(Muller et al., 2000). Particle size distributions with average particle sizes between 200 
nm and 10 µm can be fine tuned through adjusting the addition rate of the SCF (Muhrer 
et al., 2003). There also has been the report of cases where average particle size was 
independent of SCF addition rate (Fusaro et al., 2004). Muhrer’s model shows that where 
primary nucleation is dominant over secondary nucleation, the SCF addition rate will 
affect the average particle size. On the other hand, if secondary nucleation is dominant 
over primary nucleation, average particle size is independent of the SCF addition rate 
(Muhrer et al., 2002). 
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2.2.4.2. Precipitation with a compressed antisolvent (PCA) 
PCA processes can further be broken down to aerosol solvent extraction system 
(ASES), solution-enhanced dispersion by supercritical fluids (SEDS), and supercritical 
antisolvent (SAS). During a PCA process, a solution of formulation in an organic solvent 
is sprayed in the SCF where the organic solvent is miscible with the SCF and SCF is an 
antisolvent for the formulation. In comparison with GAS, smaller particles are produced 
during a PCA process with an increased surface area due to the atomization of the 
organic solution. 
2.2.4.3. Rapid expansion of supercritical solutions (RESS) 
In this technology, the SCF serves as the solvent, where the drug and additional 
stabilizers are dissolved in. The preheated mixture is passed through the saturator and is 
atomized with a heated nozzle into a collection chamber. The rapid depressurization to 
the atmospheric pressure induces the vaporization of the SCF causing homogenous 
supersaturation, nucleation, and precipitation of mono-dispersed drug particulates. The 
rapid depressurization generates an intense turbulence, which instantaneously creates 
evenly distributed supersaturation regions. The intense degree of nucleation produced 
leads to the production of small monodispersed particles (Rowe and Johnston, 2012). The 





3. Process considerations and their effects on final product 
In this section, a closer look is given to milling and spray-drying and how they 
may affect the properties of the final product.  
3.1. Milling 
During milling, the opportunities to control important product characteristics such 
as size, shape, morphology, surface properties and electrostatic charge are limited. 
However, milling processes not only reduce the particle size but also affect other 
properties of the milled material. 
3.1.1. Polymorphism 
Mechanochemical transformation is one of the concerns during milling where the 
material can undergoes polymorphic transformation or amorphization (Boldyrev, 2004). 
Another form of mechanochemical transformation, which does not directly involve 
amorphization, has been observed for talc during sonofragmentation where milled 
material release more water at low temperature and the dehydroxylation temperature 
dropped with further micronization (Pérez-Maqueda et al., 2005). Mechanochemical 
transformation occurs due to compression or impaction forces and due to elevated 
temperatures. The key determinants of this process are the milling temperature and glass 
transition temperature (Tg). The amorphization tendency of the milled material is 
increased when the milling temperature is below Tg. However, the polymorphic 
transformation from one polymorph to another is favored when the milling temperature is 
above Tg for compounds with polymorphs. Both amorphization and polymorphic 
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transformation can occur when the milling temperature is in the Tg range depending on 
the milling intensity (Descamps et al., 2007).  
This transformation may occur completely as described before, or it may occur to 
a limited degree. Even though the amorphous content is significantly small, a significant 
percentage of amorphous content is localized on the surface of the milled material. This 
transformation can significantly impact particle-particle interactions (Newell et al., 2001; 
Steckel et al., 2003; Ticehurst et al., 2000), alter flow properties (Feeley et al., 1998; 
Mackin et al., 2002), and wettability (Rasenack and Müller, 2004). Thus, it can improve 
the aqueous solubility and dissolution rate as well as compressibility (Yu, 2001).  
However, mechanochemical transformation can cause stability concerns during 
storage through the alteration of particle size distribution and specific surface area 
(Guinot and Leveiller, 1999). During post-milling storage, the particle size distribution of 
milled material may shift to the right with “surface re-crystallization” or to the left “stress 
relaxation” accordingly. The two phenomena may occur at the same time in a competitive 
manner. Milled particles form agglomerates and surface re-crystallization of amorphous 
domains on adjacent particles in these agglomerates increase their effective particle size 
with the formation of interparticulate bridges (Brodka-Pfeiffer et al., 2003). Conversely, 
stress relaxation in a single crystalline particle can be followed with the introduction of 
new fractures with the reorientation of molecules in the crystalline structure (Joshi et al., 
2002). Conditioning through modulation of storage humidity and temperature can allow 
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for controlled recrystallization of the amorphous domains on the particle surfaces 
following powder micronization (Brodka-Pfeiffer et al., 2003). 
Thermodynamic modeling has allowed the prediction of mechanochemical 
transformation for a crystalline compound where key physical properties are known 
(Wildfong et al., 2006). Moreover, this phenomenon has been reported for many 
compounds such as piroxicam (Shakhtshneider, 1997), budesonide (Dudognon et al., 
2006), naproxen (Kayaert and Van den Mooter, 2012), and indomethacin (Planins̄ek et 
al., 2010). More recently, there has been a report of amorphization as well as milling-
induced polymorphic transformation during milling process following ball milling and 
cryomilling. The polymorphic transformation can be direct, or possess a transient 
amorphization or crystalline intermediate phase. MacFhionnghaile et al. studied the 
effects of ball-milling and cryomilling on polymorphs of sulfamerazine (SMZ). 
Cryomilling of SMZ resulted in a complete amorphization; however, balling milling 
resulted in a mixture of amorphous and crystalline SMZ. Milling time also affects the 
polymorphism in SMZ in addition to milling temperature. Furthermore, authors reported 
the spontaneous formation of sulfamerazine/oxalic acid cocrystals upon storage following 
co-milling and amorphization (Macfhionnghaile et al., 2014).  
Co-milling a physical mixture of solids usually yields a solid physical mixture 
with a smaller PSD; however, this process could yield co-crystals or solid solutions. One 
of the proposed mechanisms for the formation of co-crystal from two solid phases 
involves the creation of a high interfacial area between the two, which allows for the 
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formation of a liquid phase and eventual co-crystal formation from the liquid phase. 
Further milling allows for the formation of an additional interfacial area to allow for this 
process to repeat until complete transformation into co-crystals is achieved (Chadwick et 
al., 2007). Alternatively, if each crystalline phase is expected to undergo amorphization, 
the co-milled sample will form a solid solution. As it was discussed previously, it is 
necessary for the milling temperature to be lower than the Tg for the solid solution 
(Descamps et al., 2007).  
3.1.2. Morphology 
Milling alters the shape and surface roughness of engineered particles and yields 
particle, which are rarely isometric or spherical in shape. The significances of these 
changes become apparent in the development of inhalable dry powder formulations. 
Effects of morphological changes in drug dissolution, solubility and bioavailability are 
less known; however, there is evidence that particle shape factors closely correspond with 
dissolution rates and profiles (Dali and Carstensen, 1996; Fini et al., 1995). 
3.1.3. Surface energy 
Different processing techniques (e.g. ball milling, air-jet milling, etc.) can induce 
the formation of amorphous pockets on the surface of API/excipient crystal and can have 
significant implications on the surface energy of particles (Newell et al., 2001). Surface 
energy is composed of dispersive and polar components and milling can affect each 
component to a different degree. Puri et al. showed that the dispersive components of 
surface energy for crystalline and amorphous celecoxib were approximately equal; 
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however, amorphous celecoxib had a higher polar component of surface energy in 
comparison to the crystalline form, which showed no measurable interaction. 
Furthermore, amorphous CLB absorbed a small amount of water, which is evidence for 
higher polar surface energy (Puri et al., 2010).  
3.2. Spray-drying 
3.2.1. Morphology 
Morphology of spray-dried particles is heavily dependent on drying conditions 
and material properties. Maas, et al. investigated the influence of different outlet 
temperature on the surface roughness of spray-dried mannitol particles and used confocal 
laser-scanning microscopy to quantify the surface roughness of mannitol particles. 
Different particle surface roughness was attributed to different crystallization 
mechanisms (Maas et al., 2011). The dispersion of powder is influenced by the adhesion, 
cohesion, and gas fluidization properties of the powder and it is related particle geometry 
which plays a key role in the adhesion force (Mullins et al., 1992). In comparison with 
air-jet-milled particles, spray-dried particles possess a greater extent of dispersibility due 
to a smaller contact surface between neighboring particles and a smaller radius of 
curvature (Weiler et al., 2010). Weiler et al. investigated the effect of particle 
morphology and corrugation on cohesion forces and aerosol performance of spray-dried 
powders for inhalation and showed that increasing corrugation improved dispersibility of 
the spray-dried particles with up to 90% decrease in cohesion for corrugated particles 
compared with spherical particles (Weiler et al., 2010). 
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3.2.2. Mechanical strength 
Littringer, et al. showed that spray-dried particles of mannitol showed higher 
breaking strength at higher inlet temperature and lower breaking strength at higher feed 
rates and attributed it to possible changing of the mechanism of the particle formation 
thus affecting the internal structure of particles. The prepared spray-dried particles were 
either the stable polymorph I of mannitol (96.9 %) or a mixture of polymorphs I and II 
(Littringer et al., 2012). 
3.2.3. Polymorphism  
Amorphous particles are recovered following spray drying since drying time is 
about one second or less (Van Oort and Sacchetti, 2007); however, there has been a 
report of crystalline particles following spray drying. Furthermore, altering processing 
condition such as inlet temperature (Tin) can result in the production of alternative 
polymorphs. Amorphous versus crystalline character of the powder is dependent on the 
rate of drying. Fast rate of drying results in the amorphous state of the powder or 
aggregates of small crystals and slow rate of drying results in particles composed of 
single crystal (Masuda and Ebooks Corporation, 2006). Matsuda, et al. spray-dried 
phenylbutazone from solution and obtained three different polymorphs (i.e. α, β, ε) by 
altering the Tin (Matsuda et al., 1984). Alternatively, in the case of griseofulvin, solvate 
pseudopolymorph of the compound was isolated from the drying chamber (Corrigan, 
1995). Alhalaweh, et al. developed pharmaceutical co-crystals of different APIs with 
glutaric acid, nicotinamide, succinic acid, and oxalic acid via spray drying. Simple spray 
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drying technique proved to be a viable method for the production of cocrystal and its 
scale up (Alhalaweh and Velaga, 2010).  
4. Material Properties and process selection  
As particle-engineering technologies affect the properties of the final product, 
material’s intrinsic characteristics may dictate how a material behaves while undergoing 
particle engineering. Milling and Spray-drying will be looked at to illustrate this point. 
4.1. Milling 
A mechanistic model of impact attrition of solids with a semi-brittle failure mode 
relates the attrition propensity (η), a dimensionless parameter, to material properties and 
impact conditions (Equation 6) including: the particle density (ρ), the impact velocity (v), 
the particle size (l), the hardness (H), and the fracture toughness (Kc) (Ghadiri and 
Zhang, 2002; Zhang and Ghadiri, 2002). 
 ! = !!!!"!!!  Equation 6 
As evident in Equation 6, specific powder properties such as particle size, particle 
density, hardness, friability, and fracture toughness affect the milling performance. The 
decision to choose to mill as a particle size reduction mechanism and specific milling 
method depends on material characteristics such as material hardness. Mohs scale can be 
used to categorize the material hardness qualitatively in comparison with reference 
materials (Fig. 1). Moreover, some compounds cannot be milled since milling can lead to 
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the loss of crystallinity (compaction sensitivity), melting and crystal form conversion 
(temperature sensitivity), and may also lead to a change in hydration state. 
4.1.1. Crystal lattice 
A crystalline lattice structure is made from its smallest repeating unit also known 
as a unit cell. Real crystals are not perfect and possess defects to different degrees. Point 
defects are classified as vacancies, substitutional, interstitial, and self-interstitial point 
defects. Vacancy point defects occur where there is a missing unit cell in the crystal 
lattice. If unit cells are replaced with a different atom, ion, or molecules from the ones 
forming the crystal, the defect is called substitutional point defect and is classified as 
chemical impurities. Additional lattice points made from the same, or different atom, ion, 
or molecules in the crystalline lattice are classified as self-interstitial, or interstitial point 
defects (Troy, 2005). Some defects in the crystalline lattice structure affects the milling 
behavior of the solid. For hard crystals, the breakages are predicted to occur at corners 
and edges, and the “chipping” result in a significant population of fines can lead to 
bimodal and multimodal particle size distributions. 
4.1.2. Morphology 
Particle morphology specifically aspect ratio of particles may affect the milling 
result. For example, milling needles do not lead to significant specific surface area 
increase since milling leads to breakages along the length of the particles, which only 




Solids’ densities have a direct relationship with the number of particle–particle or 
particle–wall collisions as well as the force of the collisions during milling (Bentham et 
al., 2004). Particles with higher density undergo more extensive particle size reduction. 
4.1.4. Melting point 
Material with low melting points can present significant challenges during 
milling. Mechanical milling methods with moving parts are capable of reaching 
temperatures between 40 – 60 °C (Fisher, 2013). Furthermore, they are usually associated 
with a lower hardness. Therefore, it will be harder to milling in comparison with material 
with higher melting point. 
4.1.5. Molecular weight 
The molecular weight of polymers may influence whether the polymer may be 
milled without undergoing physical and chemical changes. It is predicted that polymers 
with larger molecular weights are more susceptible to this types of changes (Gabriel et 
al., 2010).  
4.2. Spray-drying 
4.2.1. Formulation 
Intrinsic properties of liquid-feed include viscosity, surface tension, and density. 
Santa-Maria, et al. spray-dried alginate solutions with and without the presence of 
calcium, as cross-linker, and observed that higher spray solution viscosity resulted in 
bigger particle sizes. Furthermore, the addition of a surface active agent such as bovine 
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serum albumin (BSA) addition to the formulation led to smaller particle sizes after spray 
drying (Santa-Maria et al., 2012, p. -). Furthermore, hollow particles have a lower density 
in comparison to solid particles and will have smaller aerodynamic diameter compared to 
their solid counterpart. Fig. 3 depicts a patented example of these particles developed by 
Nektar Therapeutics. In PulmoSphere® technology, spray-dried particles of drug particles 
are created by spray-drying an emulsion of perfluorocarbons, water, along with the drug. 
The sudden removal of low boiling point fluorocarbon causes the perforation of the 
particles (Miller and Gil, 2012). These particles are low-density and porous with 
geometric diameters of 3-5 µm; however, their aerodynamic particle size is, and they 
possess excellent dispersibility compared with carrier-less micronized formulations 
allowing for high dose delivery of inhalation formulations due to decreased contact and 
presence of rough surfaces on the particles and they are depicted in Fig. 3 (Dellamary et 
al., 2000). Corrugation, also known as surface roughness, is attributed to higher 
dispersibility of spray-dried powders for inhalation is attributed to lower particle 
cohesion and a reduced total accessible area for adhesion. Weiler et. al. produced spray-
dried particles with different morphology and surface corrugation (Weiler et al., 2010). 
4.2.2. Melting point 
Drug melting point is a key parameter, which dictates whether a material can be 
spray-dried, or not. Drugs with low melting point may not be processed using spray 
drying where the outlet temperature of the spray drying processing is greater than the 
drug’s melting point.  
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4.2.3. Glass transition temperature 
Furthermore, it is not advised to conduct spray drying above the glass transition 
temperature (Tg) for a solid. Doing so may yield solid-like glasses or highly supercooled, 
viscous liquids. As a plasticizer, moisture content significantly alters the Tg thus altering 
the processability of the solid (Roos, 2002). 
5. Conclusion: 
Particle engineering techniques allow for top-down and bottom-up processing of 
pharmaceutical solids. Additionally, final product’s attributes may be affected by the 
processing technique. Additionally, material’s intrinsic properties may limit the 
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Figure 1.1: The upper limit of material hardness on Mohs hardness scale that different 
types of dry milling equipment can process 
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Table 1.1: Approximate particle size obtainable by various milling techniques. Adapted 
from (Zheng, 2009), with permission of John Wiley & Sons Inc. 
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1. Overall objective 
Ibuprofen (IBU) is a non-steroidal anti-inflammatory agent (NSAID) is generally 
administered orally as tablets and suspensions. It is indicated for pain, fever, and other 
inflammatory conditions. More recently, a slower rate of respiratory decline is shown in 
cystic fibrosis (CF) patients on high, oral doses of IBU in comparison to placebo. The use 
of this treatment modality has not been well adopted or widespread due to high doses, 
side effects, contraindications, and black box warnings regarding the use of IBU. 
 Pulmonary delivery may be an attractive alternative to high-dose oral 
administration in CF since lungs are the desired targets for the anti-inflammatory and 
antibiotic activities of IBU. Typically with inhaled powders, a binary formulation of a 
drug with a carrier, such as lactose, significantly improves their performance; however, 
this strategy is not practical for the delivery of a large drug dose via a dry powder inhaler 
(DPI). Other inhalation devices such as nebulizers require significantly more time for 
drug delivery, and metered dose inhalers may be incapable of metering sufficiently large 
drug doses. Therefore, carrier-free DPIs have been explored for large drug dose delivery.  
IBU exists as the stable polymorph I (in its acicular crystal habit), or as the less 
stable polymorph II. Low melting point (75.85°C), water solubility, and crystal habit of 
ibuprofen makes its processing challenging. For instance, spray drying could not be used 
to produce the carrier-free ibuprofen DPI formulation as the smallest particle size 
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produced using a design of experiment approach with the smallest particle size (D50) 
between 10 and 20 µm. The overall objective of this dissertation was to develop a carrier-
free DPI formulation of IBU with an acceptable flowability and in-vitro aerodynamic 
performance determined by Next Generation Impactor.  
2. Supportive objective 
Indomethacin and diclofenac could serve as alternatives to ibuprofen for the 
development of carrier-free DPI formulation. Supportive objective of this dissertation 
was to evaluate the feasibility of for the development of carrier-free DPI formulation. 
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Abstract 
Objective: To optimize air-jet milling conditions of ibuprofen (IBU) using design of 
experiment (DoE) method, and to test the generalizability of the optimized conditions for 
the processing of another non-steroidal anti-inflammatory drug (NSAID). 
Methods: Bulk IBU was micronized using an Aljet mill according to a circumscribed 
central composite (CCC) design with grinding and pushing nozzle pressures (GrindP, 
PushP) varying from 20 to 110 psi. Output variables included yield and particle diameters 
at the 50th and 90th percentile (D50, D90). Following data analysis, the optimized 
conditions were identified and tested to produce IBU particles with a minimum size and 
an acceptable yield. Finally, indomethacin (IND) was milled using the optimized 
conditions as well as the control.   
Results: CCC design included eight successful runs for milling IBU from the ten total 
runs due to powder “blowback” from the feed hopper. DoE analysis allowed the 
optimization of the GrindP and PushP at 75 and 65 psi. In subsequent validation 
experiments using the optimized conditions, the experimental D50 and D90 values (1.9 and 
3.6 µm) corresponded closely with the DoE modeling predicted values. Additionally, the 
optimized conditions were superior over the control conditions for the micronization of 
IND where smaller D50 and D90 values (1.2 and 2.7 µm vs. 1.8 and 4.4 µm) were 
produced. 
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Conclusion: The optimization of a single-step air-jet milling of IBU using the DoE 
approach elucidated the optimal milling conditions, which were used to micronize IND 
using the optimized milling conditions.   
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1 Introduction 
Successful deep lung deposition for dry powder inhaler (DPI) formulations, is 
strongly correlated to the percentage of particles with an aerodynamic diameter (Dae) less 
than 3 µm (Newman and Chan, 2008). As depicted in Equation 1, for spherical, solid 
particles, the aerodynamic diameter is equal to the geometric diameter (Deq) where 
particle density (ρp) is equal to unit density (ρo) and the dynamic shape factor (χ) is equal 
to one (Telko and Hickey, 2005).  
 !!" =  !!"  !!!! ! (Equation 1)  
Microparticles with geometric diameters less than 3 µm can be produced via top-
down approaches, such as an air-jet mill, as well as bottom-up approaches, such as a 
controlled crystallization method (Merisko-Liversidge and Liversidge, 2011; Rasenack et 
al., 2003). Top-down approaches include: mechanical mills where the milling energy is 
imparted directly, fluid energy mills where the milling energy is imparted indirectly, and 
high-pressure homogenizers where the milling energy is imparted both directly and 
indirectly (Moribe et al., 2013; Naik and Chaudhuri, 2015). An air-jet mill is an example 
of a fluid energy mill and is composed of a milling chamber where the powder is fed in 
through a hopper via a pushing nozzle, and particle collisions and fractures are caused by 
the introduction of one or more milling nozzles (Muller et al., 1996).  
Fracture inducing mechanisms can be classified as impaction, compression, or 
attrition (Naik and Chaudhuri, 2015). During impaction and compression, the fracture 
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inducing force is applied normal to the surface, leading to the formation of two or more 
fragments; however, it is applied parallel to the surface during attrition, and it results in 
the production of extremely fine particles (Parrott, 1974). As opposed to the mechanical 
mills where impaction, compression, and attrition are all responsible for milling, in an 
air-jet mill only attrition is responsible for milling.  
The extent of milling for a material is dependent on its mechanical properties, 
initial particle size distribution (PSD) and the milling conditions (Saleem and Smyth, 
2010; Vatsaraj et al., 2003). If material experiences plastic deformation before fracture, it 
is classified as ductile; otherwise, it is classified as brittle. Brittle fracture is a function of 
temperature, strain rate, stress state, and particle size (Larsson and Kristensen, 2000). The 
brittle-ductile transition occurs at the critical particle diameter, below which particles 
undergo a ductile fracture as opposed to a brittle fracture during milling, with an 
increased energy requirement (Kendall, 1978). The critical diameter characterizing the 
brittle-ductile transition for ibuprofen (IBU) is reported as 854 µm (Leuenberger, 1982) 
and more recently between 125 – 355 µm (Larsson and Kristensen, 2000), which makes 
milling IBU more difficult than other solids with smaller brittle-ductile transition critical 
diameters (Roberts and Rowe, 1987). 
IBU, 2(4-isobutylphenyl)propanoic acid, has a molecular weight (MW) of 206.29 
g/mol and is commercially available as a racemic mixture of S(+)-IBU 
(pharmacologically active) and R(-)-IBU (pharmacologically inactive) (Neupert et al., 
1997). IBU exists either as the stable polymorph I with a melting point (MP) of 75.85°C, 
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or as the less stable polymorph II, with a lower MP of 16.85°C (Dudognon et al., 2008). 
Previously, micronized IBU has been produced, and companies such as BASF have 
reported the minimum particle diameters at the 10th, 50th, and 90th percentile (D10, D50, 
and D90) at around 10, 25, 65 µm respectively (BASF Group, n.d.). Furthermore, Shariare 
et al. reported air-jet milling of a < 40 µm sieve fraction to a D10, D50, and D90 of 0.75, 
2.25, and 4.10 µm respectively where the starting particles were needle-shaped with a 
high degree of crystalline imperfection (Shariare et al., 2012). Even though these 
materials may eventually be suitable for inhalation, multiple steps of crystallization, 
drying, sieving, and micronization were required to reach this PSD profile. In addition, 
the poor flowability of raw materials due to shape and their physical instability due to 
crystalline imperfections may not enable industrialization of such an approach. 
Alternatively, the optimization of milling such that appropriate particle sizes can be 
obtained using a single milling step is highly desirable and can be more easily 
commercialized.  
In this research, we investigated the micronization of a bulk pharmaceutical grade 
of IBU via air-jet milling, by the application of a design of experiments (DoE) statistical 
method of optimization, and we increased batch sizes to evaluate its effect on the particle 
size distribution (PSD). Furthermore, we applied the optimized conditions for the 
micronization of indomethacin (IND), another non-steroidal anti-inflammatory drug with 
different physicochemical properties. Our research hypothesis was that the optimized 
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conditions for the air-jet milling of IBU, a physically difficult material to micronize, 
could be used to mill IND with different physical and mechanical properties.  
2 Methods 
IBU, USP, was purchased from Letco Medical (Decatur, Alabama). IND 
(pharmaceutical grade, Parafarm, Saporiti, Buenos Aires, Argentina) was a generous 
donation from collaborators in Argentina. Scintillation vials (Wheaton, Millville, NJ) 
were used for the collection and the storage of the micronized powder. Tween 20, 
Sodium Lauryl Sulfate (SLS), and hydrochloric acid (HCl) were purchased from Fisher 
Scientific (Pittsburgh, PA). House deionized water was used for the preparation of 
suspensions. For scanning electron microscopy (SEM) imaging, standard aluminum stubs 
were purchased from Electron Microscopy Sciences (Hatfield, PA). 
2.1 Air-jet milling  
A Model 00 Jet-O-MizerTM (also known as Aljet mill, Fluid Energy, Telford, PA) 
was configured according to Figure 3.1, and it was used to micronize IBU and IND. For 
milling IBU, the milling conditions were varied between 20 and 110 psi for the pushing 
and grinding nozzle pressures (Vatsaraj et al., 2003). Throughout the DoE runs, the feed 
rate of 1 g/min and the batch size of 5 g were used. The milled powder samples were 
collected from the different segments of the jet mill in a desiccator under vacuum. The 
samples were from the segments illustrated in Figure 3.1: the tube after grinding chamber 
(bfC), the cyclone (C), the collection vessel adapter (D), the collection bag adapter (E), 
the collection vessel (G), and the collection bag (H). Following the powder collection, the 
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yield percentage for each segment as well as the overall yield was calculated according to 
the Equation 2 where mR is the recovered mass from the respective segment or the overall 
recovered mass and m is the total processed mass: 
 Yield =  !!! × 100 (Equation 2)  
The DoE analysis results were used to predict the milling conditions allowing the 
maximum particle size reduction. For the scale-up experiments and testing the DoE 
predictions, the milling runs were conducted on IBU batch sizes of 5, 10, and 20 g using 
the optimized conditions from the DoE. Additionally, two 5 g batches of indomethacin 
(IND) were milled using the optimized conditions, as well as the worst milling 
conditions, as determined by the DoE. 
2.2 DoE 
Circumscribed central composite (CCC) experimental design with two center 
points was developed in JMP Pro 10 (SAS Institute Inc., Cary, North Carolina) statistical 
software. In a previous air-jet milling study, authors suggested to maximize attrition 
between particles, the grinding nozzle pressures could be set at the same pressure level 
(Vatsaraj et al., 2003). Therefore, both grinding nozzle pressures were grouped together 
as one variable, and along with the pushing nozzle pressure, were the two studied factors. 
With a CCC axial value of 1.414 for two factors (NIST/SEMATECH e-Handbook of 
Statistical Methods, n.d.) and the initial factor values ranging between 35 and 95 psi, the 
experimental design runs were randomized and tabulated, and the factors’ values were 
rounded to multiples of five. The values for grinding and pushing nozzle pressures ranged 
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from 20 to 110 psi (Table 3.1). The analyzed responses included: the yield, D50, and D90 
values associated with the PSD for the recovered samples.  
2.3 PSD analysis by Laser light diffraction 
PSDs were determined using a Sympatec Helos equipped with a Cuvette module 
(System-Partikel-Technik GmbH, Clausthal-Zellerfeld, Germany). Data were analyzed 
using the Sympatec WINDOX software. For each measurement per a previously 
optimized method, about 2 mg of powder was dispersed in 0.5 mL of 0.1 % (w/v) SLS in 
water and the sample was sonicated for 5 minutes. A reference measurement was 
performed on the cell filled with 50 mL of 0.005 % (v/v) Tween 20 and 50 µL of 2.5 N 
HCl in water. After the reference measurement, 50 µL aliquots of the sonicated 
suspension were added to the cell to achieve optical concentrations of between 10 to 20 
% and the total of six measurements were performed on each sample. Analyzed samples 
included: unprocessed IBU and IND as well as the milled samples from the bfC, C, D, E, 
G, and H segments for each run. The span value was calculated according to the 
following formula: 
 !"!" =  !!"!!!"!!"  Equation 3 
To estimate the overall D10, D50, and D90 values for the combined recovered 
fractions associated with each run, stacked bar charts were graphed and herein are 
referred to as the yield normalized cumulative PSDs. Each stacked bar corresponded to a 
particle size bin and its height corresponded to the volume density distributions’ weighted 
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averages by the yield for each segment of the jet mill. The D10, D50, and D90 values for 
the normalized cumulative PSDs were the particle sizes corresponding to the 10, 50, and 
90 % area of the stacked bar chart respectively. This method was validated through the 
calculation of these values for a single PSD using this method and their comparison with 
the calculated values using the Sympatec WINDOX software.  
2.4 Scanning Electron Microscopy (SEM) 
Samples were mounted on standard aluminum SEM stubs, were sputter coated 
with 15 nm platinum/palladium (Pt/Pd) using a Cressington sputter coater 208 HR 
(Cressington Scientific Instruments Ltd., Watford, UK) and were imaged using a Zeiss 
Supra 40VP SEM (Carl Zeiss Microscopy GmbH, Jena, Germany). 
3 Results 
3.1 Air-jet milling 
The 4th and 10th runs were unsuccessful due to powder “blowback,” where 
grinding nozzle pressures were significantly larger than the push nozzle pressure (65 vs. 
20 psi and 95 vs. 35 psi). Due to the adhesion of IBU throughout the interior surface of 
the jet mill downstream from the milling chamber (Figure 3.1), milled samples from the 
different segments were collected individually. The overall yields ranged from 64.5 to 





3.2 DoE analysis 
The primary goals of the DoE analysis were to minimize the D50 and D90 values 
of the PSDs and to maximize the collection bag yield percentage. Since the PSDs for the 
collection bag fraction were associated with the smallest D50 and D90 values, they were 
utilized for the DoE analysis. For the collection bag fraction, the D50 values ranged from 
3.2 to 11.9 µm, and the D90 values ranged from 8.1 to 92.4 µm (Figure 3.3). Following 
the DoE analysis, it was determined that the grinding and pushing nozzle pressures have 
a significant effect on D90 (p = 0.0046*, 0.0090*) and the grinding nozzle pressure had a 
second-degree effect on D90 (p = 0.0064*). The D50 and D90 values for the yield 
normalized cumulative PSDs ranged from 6.4 to 12.5 µm for D50 and 13.2 to 27.2 µm for 
D90 (Figure 3.4). 
The prediction profiler graphs were generated by the JMP software (Figures 3.5 -
3.8) and predicted the collection bag yield, D50, and D90 values as a function of the 
grinding and pushing nozzle pressures. To test the DoE analysis, the optimal collection 
bag yield and the PSD parameters were predicted for the grinding nozzle pressure of 75 
psi and the pushing nozzle pressure of 65 psi. Specifically, Figure 3.5 illustrates the 
prediction profiler for the overall and the collection bag yields. Likewise, Figures 3.6 – 
3.8 illustrate the prediction profiler graphs for the D50 and D90 values for the PSDs 
associated with: the cyclone fraction (Figure 3.6), the collection bag fraction (Figure 3.7), 
and the yield normalized cumulative PSD (Figure 3.8).  
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3.3 DoE testing and batch size 
The DoE predictions were tested through milling a 5 g batch of IBU with a 
grinding nozzle pressure of 75 psi and a pushing nozzle pressure of 65 psi. The yield 
percentages, PSDs, and yield normalized cumulative PSD from the different segments of 
the air-jet mill are presented in Figures 3.10 and 3.11. Furthermore, milling was 
conducted on 10 and 20 g batches of IBU as well as 5 g batches of IND. The collection 
bag yield, D50, D90, and span values are presented in Table 3.3.  
3.4 Scanning Electron Microscopy (SEM) 
The unprocessed IBU particles had a smooth acicular morphology with an 
approximate length of 150 µm and an approximate cross section of 20 x 20 µm. The 
milled IBU particles from the collection bag sizes ranged from 1 µm to greater than 5 µm 
with at least one smooth dimension and one or more rough dimensions. As opposed to the 
unprocessed IBU particles, the milled IBU particles existed as particle agglomerates of at 
least 20 to 30 µm (Figure 3.12). 
4 Discussion  
The DoE method allowed for the IBU milling conditions optimization and led to a 
PSD with the D50 and D90 values significantly bellow the brittle-ductile transition critical 
diameter of IBU where dry milling below this size is more difficult (Shariare et al., 
2012). At the grinding nozzle pressure of 75 psi and the pushing nozzle pressure of 65 
psi, the prediction profilers (Figures 3.5 – 3.8) predicted the maximal yield for the 
collection bag fraction, the smallest D50 value for the cyclone and the collection bag 
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fraction PSD, and the smallest D50 and D90 value for the yield normalized cumulative 
PSD. The collection bag and the overall yields from the DoE testing experiment 
corresponded closely with the yields predicted by the prediction profilers (Figure 3.5 and 
10, 16 vs. 16.7 %, and 79.4 vs. 80.3 %). On the other hand, the D50 and D90 values for the 
collection bag fraction from the DoE testing experiment were less than the D50 and D90 
values predicted by the prediction profiler (Figure 3.7 and Table 3.3, 1.9 vs. 4.36 µm and 
3.6 vs. 5.48 µm). As depicted in Table 3.3, the collection bag fraction D50 and D90 values 
increased with increasing batch sizes. The D50 and D90 values for the 20 g batch agreed 
more closely with the predicted values using the prediction profiler. Batch size 
independent processing conditions are advantageous during scale up in the 
pharmaceutical industry. 
During milling using the optimized conditions, the collection jar and the 
collection bag fractions had a left-shifted PSD in comparison with the other fractions 
(Figure 3.11). This shift was responsible for the formation of a bimodal distribution in the 
yield normalized cumulative PSD (Figure 3.10). Fine IBU aggregates deposition in the 
collection jar versus fine IBU particles deposition in the collection bag could explain 
similar PSDs for these two fractions. In contrast with the D90 values of the collection bag 
fractions, the yield normalized cumulative PSDs D90 values did not exceed 30 µm (Figure 
3.3 – 3.4). Since the collection bag yields were about 10 %, the larger particles effects on 
the yield normalized cumulative PSDs D90 values became smaller (Figure 3.2).  
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For each DoE run, a pressure index (PI) value (Equation 4) was calculated where 
P0 was set to 1 psi; these values are tabulated in Table 3.2. Similar pressure ratios have 
been previously calculated (Magee et al., 2008).  
 !"#$$%"# !"#$% = log !"#$%!"# !"##$% !"#$$%"#!!"#!!"# !"##$% !"#$$%"# ∙ !! Equation 4 
There was a good correlation (R2 = 0.83) between the cyclone yield and the PI 
values (Figure 3.9). A decrease in the PI value was associated with an increase in the 
flow level through the cyclone, thereby increasing the likelihood to impact and to trap the 
largest particles on the cyclone wall. The two largest PI values (2.32 & 2.41) were 
associated with the 4th and 10th runs (Table 3.2), which were terminated due to powder 
blowback. These PI values were followed by the PI value for the 1st run (2.27), which 
was conducted successfully. Accordingly, the powder blowback inducing PI value lies 
between 2.27 and 2.32.  
Furthermore, there was a good correlation (R2 = 0.71) between the collection bag 
fraction D90 and the PI values. Previously, it was reported that the pushing nozzle 
pressure does not influence the particle size as significantly as the grinding nozzle 
pressure (Saleem and Smyth, 2010; Vatsaraj et al., 2003). Low grinding and high pushing 
nozzle pressures correspond with low PI values and were associated with the collection 
bag D90 values close to the unprocessed material (Figure 3.3). Decreasing the grinding 
nozzle pressure reduced the frequencies of the particle-particle and the particle-wall 
collisions and decreased the milling efficiency (Teng et al., 2009). Moreover, an increase 
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in the pushing nozzle pressure is associated with a less efficient particle size reduction 
caused by a shorter sample residence time in the grinding chamber (Muller et al., 1996).  
The overall yields for the DoE runs were greater than 80 % except for the first 
run. Additionally, the collection bag yield improved over the coordinates of the design 
space (maximum of 16.1 %). However, the collection bag yield was greater than 15 % 
only for the central points (Figure 3.2). For the DoE optimized parameters, increasing 
batch sizes from 5 to 20 g improved the yield from 16.1 to 29 % (Table 3.3). The low 
collection bag yields were due to IBU’s tendency to adhere to the walls of processing 
equipments. Furthermore, we observed different deposition patterns on the air-jet mill 
segments over the design space where the particle sizes associated with each segment 
was different from others. The low collection bag yields are permissible since IBU is a 
low-cost API. The critical output variables are the D50 and D90 here and it is expected that 
the collection bag yield would improve further with the batch size increase. Additionally, 
bulk IBU with different starting particle sizes and double milling could be used to 
increase the collection bag yield (Clark et al., 1998; Xu et al., 2010).  
In comparison with the IBU milling using the optimized conditions, the IND 
milling yielded smaller particles, where the D90 value was less than 3 µm and the D50 
value was about 1 µm. Moreover, the least favorable milling conditions based on the DoE 
led to the micronization of IND; however, the micronization was not as efficient as the 
optimized conditions and the PSD possessed a larger span. IND would less likely 
undergo the ductile mode of fracture due to a higher strength of crystal lattice than IBU 
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with an MP of 158 °C, which is almost twice the MP for IBU (Jansook et al., 2010; 
Katritzky et al., 2001). Furthermore, IND has a more brittle crystalline structure than IBU 
since it underwent a higher degree of comminution than IBU. This observation is 
supported by a smaller predicted brittle-ductile transition critical diameter for IND in 
comparison with IBU. At particle sizes above this diameter, IND undergoes the brittle 
mode of fracture, whereas IBU undergoes the ductile mode of fracture (Troy, 2005). 
However, the smaller initial D50 and D90 values for IND could be a contributory factor for 
the smaller final D50 and D90 values for IND in comparison with IBU.  
5 Conclusion 
Being a soft solid with a low MP, IBU has a large brittle-ductile transition critical 
diameter. IBU showed to be a good model drug for the optimization of a single-step air-
jet milling. The DoE method allowed for the optimization of the milling conditions, 
which were used for the micronization of IBU and IND. Furthermore, the calculated PI 
values predicted failed runs as well as particle trapping in the cyclone for the Aljet mill. 
Increasing IBU batch sizes improved the collection bag fraction yield with the relative 
preservation of PSD. In future studies, the in vitro aerodynamic performance and the 
stability of the micronized IBU will be investigated to develop a carrier-free, high-dose 
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Figure 3.1: The Aljet mill configuration: the tube after grinding chamber (bfC), the 
cyclone (C), the collection vessel adapter (D), the collection bag adapter (E), the 




Figure 3.2: The (A) overall and (B) collection bag yields and the corresponding pushing 





Figure 3.3: The (A) D50 (µm) and (B) D90 (µm) for the collection bag particle size 
distribution and the corresponding pushing and grinding nozzle pressures (psi) for the air-





Figure 3.4: The (A) D50 (µm) and (B) D90 (µm) for the yield normalized cumulative 
particle size distribution and the corresponding pushing and grinding nozzle pressures 






Figure 3.5: The prediction profilers for the collection bag (Yield_H) and the overall 




Figure 3.6: The prediction profilers for the D50 (µm) and D90 (µm) of the cyclone particle 




Figure 3.7: The prediction profilers for the D50 (µm) and D90 (µm) of the collection bag 





Figure 3.8: The prediction profilers for the D50 (µm) and D90 (µm) of the yield 
normalized cumulative particle size distribution as functions of the grinding and the 




Figure 3.9: (A) The cyclone yield (%) and (B) the collection bag D90 (µm) values as a 
function of the pressure index (PI), where PI = log (Grinding nozzle pressure2/Pushing 




Figure 3.10: The yield normalized cumulative particle size distribution of the jet-milled 
ibuprofen and the associated yields (%) from the different segments of the jet mill 
including: the tube after grinding chamber (bfC), the cyclone (C), the collection vessel 





Figure 3.11: The particle size distributions of the unprocessed ibuprofen (IBU) and the 
IBU samples from the different segments of the jet mill including: the tube after grinding 
chamber (bfC), the cyclone (C), the collection vessel adapter (D), the collection bag 




Figure 3.12: The scanning electron microscopy images of: A, B) the unprocessed 
ibuprofen; C, D) the jet-milled ibuprofen.  
	 84	
Table 3.1: The circumscribed central composite experimental design with two center 
points 
Run # Grinding Nozzle Pressure (psi) 
Pushing nozzle 
Pressure (psi) 
1 110 65 
2 65 110 
3 35 95 
4 65 20 
5 35 35 
6 95 95 
7 65 65 
8 20 65 
9 65 65 
10 95 35 
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Table 3.2: The Circumscribed central composite experimental design with two center 
points with the Pressure Index (PI) calculation for each run where PI = log (Grinding 
nozzle pressure2/Pushing nozzle pressure x P0), and P0 = 1 psi. 




1 110 65 2.27 
2 65 110 1.58 
3 35 95 1.11 
4 65 20 2.32 
5 35 35 1.54 
6 95 95 1.98 
7 65 65 1.81 
8 20 65 0.79 
9 65 65 1.81 
10 95 35 2.41 
  
	 86	
Table 3.3: The collection bag yield, the D50, the D90, and the span values for 5, 10, 20 g 





(psi) Yield (%) D50 (µm) D90 (µm) Span 
Stock IBU - - - 48.0 106.7 1.8 
IBU 5g 75 65 16.1 1.9 3.6 1.5 
IBU 10g 75 65 17.4 2.2 4.2 1.5 
IBU 20g 75 65 29.0 2.7 6.0 1.8 
Stock IND - - - 26.3 64.8 2.3 
IND+ 5g 75 65 2.3 1.2 2.7 1.7 
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Objective: To investigate influences of capsule fill weight, batch size, and storage 
conditions on in vitro aerodynamic performance of jet-milled ibuprofen (IBU) carrier-
free, dry powder inhaler formulations. 
Materials and methods: Milled and unmilled IBU samples were characterized thermally 
and spectroscopically. Physicochemical characterization was performed by quantifying 
specific surface area, density, and angle of repose. Performance testing was conducted on 
IBU formulations in combination with a high resistance Monodose RS01 using Next 
Generation Impactor. 
Results and discussion: There were no detectable differences between IBU samples 
thermally and spectroscopically. The milled IBU sample exhibited improved powder 
flow in comparison with the unmilled sample. The milled IBU powders possessed 
surprisingly high in vitro aerodynamic performance with a fine particle fraction 
percentage between 67 and 85 %, and a minimum respirable fraction percentage of 49 %. 
The capsule fill weights, from 10 to 50 mg, and milling batch sizes did not significantly 
influence performance. The importance of powder conditioning following milling was 
illustrated as the storage duration and temperature negatively affected performance.  
Conclusion: In vitro aerodynamic performance of IBU is independent of capsule fill 
weight and batch size; however, some period of powder conditioning is recommended to 




Ibuprofen (IBU) is a non-steroidal anti-inflammatory agent (NSAID) indicated for 
pain, fever, and other inflammatory conditions such as osteoarthritis, rheumatoid arthritis, 
and pericarditis (Lexi-Comp, 2015). Additionally, a slower rate of respiratory decline is 
shown in cystic fibrosis (CF) patients on high, oral doses of IBU in comparison to 
placebo (Konstan et al., 1995; Lands et al., 2007). More recently, Shah et al. showed that 
IBU acts synergistically with other antibiotics, and may play a multifunctional role in the 
treatment of CF lung infections (Shah et al., 2015). Even though IBU holds promise in 
the management of CF, the use of this treatment modality has not been well-adopted or 
widespread. From 1995 to 2005, the frequency of use of oral, high-dose IBU remained 
low (3.6 vs. 3.3 %) according to an epidemiologic study of CF patients (Konstan et al., 
2010). High doses, side effects, contraindications, and black box warnings regarding the 
use of IBU in patients with a moderate to severe renal impairment, or with an increased 
risk of upper gastrointestinal (GI) bleeding (Bhala et al., 2013; Lexi-Comp, 2015), may 
be responsible for this apparent under-prescribing and underuse in this patient population.  
Pulmonary delivery may be an attractive alternative to high-dose oral 
administration in CF (Konstan et al., 1995) since lungs are the desired targets for the anti-
inflammatory and antibiotic activities of IBU and inhalation therapy is already well 
accepted in CF patients (Agent and Parrott, 2015). Inhalation route is well-known to be 
associated with pharmacokinetic advantages, requiring a decreased administered dose for 
an equivalent pharmacological effect in the lungs compared to oral or systemic routes 
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(Smyth et al., 2007). In comparison with oral and systemic administrations, inhalation 
administration can provide a dosing advantage between 10 and 24 fold and may be able 
to minimize the systemic risks related to conventional high-dose IBU therapy (Bhala et 
al., 2013; Smyth et al., 2007; Telko and Hickey, 2007). Pulmonary delivery of IBU will 
minimize GI adverse drug reactions by eliminating direct GI toxicity (Matsui et al., 
2011). Typically with inhaled powders, a binary formulation of a drug with a carrier, 
such as lactose, significantly improves their performance (Hickey et al., 2007; Hira et al., 
2010; Steckel and Bolzen, 2004). However, this strategy is not practical for the delivery 
of a large drug dose via a dry powder inhaler (DPI). Other inhalation devices such as 
nebulizers require significantly more time for drug delivery (Geller et al., 2011), and 
metered dose inhalers may be incapable of metering sufficiently large drug doses (Smyth, 
2005). Therefore, carrier-free DPIs have been explored for large drug dose delivery 
(Healy et al., 2014). 
In this study, we explored the potential for delivering IBU in a carrier-free 
system. Jet-milled IBU samples were characterized, and effects of capsule fill weight (i.e. 
loaded dose), air-jet milling batch size, and formulation aging/conditioning on the in vitro 
aerodynamic performance of carrier-free, high-dose DPI formulations of IBU were 
investigated. For simplicity in these studies, a capsule-based DPI was used. Capsule-
based inhalation systems require individual capsules to have adequate powder loading to 
avoid multiple administrations and to decrease administration burden for high-dose DPI 
delivery. Previously, it has been shown that capsule-based DPI device air flow resistance 
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is dependent on the capsule fill weight (Yazdi and Smyth, 2015). However, the effect of 
capsule fill weight on in vitro aerodynamic performance has not been reported despite the 
knowledge that in vitro aerodynamic performance is affected by changes in device 
resistance (Adams et al., 2012). Air-jet milling is considered a batch manufacturing 
process where batch size and batch-to-batch variability may significantly influence 
physicochemical characteristics of milled powders (Lee et al., 2015). Additionally, 
powder handling may affect these characteristics within a single batch (Marek et al., 
2011). Even though these changes may not be detectable with standard characterization 
methods, they may affect performance of DPIs during formulations (Ticehurst et al., 
1994). Finally, milling disturbs integrity of crystalline material, and post-milling storage 
alters particle size through “surface re-crystallization” and “stress relaxation” (Ward and 
Schultz, 1995). Surface re-crystallization of amorphous domains on adjacent particles and 
resultant interparticulate bridges increase effective particle size (Brodka-Pfeiffer et al., 
2003). Conversely, stress relaxation of milled material decreases particle size through 
introduction of new fractures and subsequent reorientation of molecules in crystalline 
structure (Joshi et al., 2002). Both phenomena alter DPI performance, and their degree of 
presence should be evaluated during post-milling storage. Our research hypothesis is that 
the in vitro aerodynamic performance, and thereby the expected in vivo performance, of 
carrier-free, high-dose DPI formulations may be affected by capsule fill weight, air-jet 
milling batch size, and formulation aging. 
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2 Materials and methods 
Unprocessed IBU, USP (Letco Medical, Decatur, Alabama) served as a control in 
the physicochemical characterization. IBU samples were micronized via air-jet milling 
(Model 00 Jet-O-MizerTM also known as Aljet mill, Fluid Energy, Telford, PA, USA). 
The samples included the milled IBU from 5, 10, and 20 g batches (IBU5, IBU10.1, 
IBU10.2, IBU20) as depicted in Table 4.1. The particle size distribution (PSD) D10, D50, 
and D90 values for each sample were defined as particle diameters at the 10th, 50th, and 
90th percentile and the span value was calculated according to Equation 1: 
 !"#$ =  !!"!!!"!!"  (1) 
2.1 Scanning electron microscopy (SEM) 
The milled samples (IBU5, IBU10.1, IBU10.2, and IBU20) were mounted on 
standard aluminum SEM stubs, were sputter coated with 15 nm platinum/palladium 
(Pt/Pd) using a Cressington sputter coater 208 HR (Cressington Scientific Instruments 
Ltd., Watford, UK) and were imaged using a Zeiss Supra 40VP SEM (Carl Zeiss 
Microscopy GmbH, Jena, Germany). 
2.2 X-Ray powder diffraction (XRD) 
Two-dimensional X-Ray diffractograms for the milled samples (IBU5, IBU10.1, 
IBU10.2, and IBU20) were obtained using an automatic R-Axis Spider (Rigaku 
Corporation, Tokyo, Japan), an X-ray single crystal diffractometer controlled by RINT 
Rapid software with target radiation of Copper at 40 KV voltage and 40mA current. The 
samples were suspended in light mineral oil and were loaded on loops epoxied to 
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conventional goniometer bases. Additionally, a background X-Ray diffractogram of light 
mineral oil loaded on the loops was subtracted from sample diffractograms, one-
dimensional 2θ diffractograms were generated, and .txt files were saved using 2DP 
Software (Ragaku Corporation, Tokyo, Japan). To analyze the one-dimensional 
diffractograms using Jade (Ragaku Corporation, Tokyo, Japan), .raw files were generated 
from .txt files using the ConvX.exe (Mark Bowden, Industrial Research Ltd., Lower Hutt, 
New Zealand). 
2.3 Differential scanning calorimetry (DSC)  
For the sample IBU20 and unmilled IBU, thermograms were obtained using an 
Auto Q20 (TA Instruments-Waters LLC, New Castle, DE, USA) differential scanning 
calorimeter controlled by the TA Advantage Software (TA Instruments-Waters LLC, 
New Castle, DE, USA) and equipped with a RCS40 (TA Instruments-Waters LLC, New 
Castle, DE, USA) refrigerated cooling system with nitrogen purge of 50 mL/min. About 
4 mg of each sample were loaded in standard DSC pans (DSC Consumables Inc., Austin, 
MN, USA) and were crimped using a Tzero sample press (TA Instruments-Waters LLC, 
New Castle, DE, USA). Samples were heated at the rate of 10° C/min from 30°C to 
100°C. 
2.4 Fourier transform infrared spectroscopy (FT-IR) 
For the sample IBU20 and unmilled IBU, FT-IR spectra were obtained using a 
NicoletTM iSTM50 FT-IR Spectrometer (Thermo Fisher Scientific Inc., Madison, WI, 
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USA) equipped with a germanium Attenuated Total Reflection (ATR) accessory and a 
pressure tower. 
2.5 Powder characterization 
Physicochemical characterization was conducted on the sample IBU20, as a 
representation of the other milled samples, as well as the unmilled IBU by quantifying 
specific surface area (SSA), density, and angle of repose. IBU20 was chosen for this 
purpose as it possessed similar particle size distribution in comparison with the two other 
batch sizes while making available the largest quantity of powder for analysis. 
  
2.5.1 Brunauer-Emmett-Teller  
Surface area (SA) was evaluated via a single-point BET method using a 
Monosorb® surface area analyzer (Quantrachrome Instruments; FL, USA) following 24 h 
outgassing with helium at room temperature (RT) before each measurement in triplicate 
on a known powder mass (m). SSA was calculated using Equation 2:  
 !!" = !"!  (2) 
2.5.2 Helium pycnometry 
True densities were measured using an MVP-D160-E multipycnometer 
(Quantrachrome Instruments; FL, USA) equipped with the micro cell and adapter. 
Measurements were conducted in triplicate. Before pressure measurements, the 
multipycnometer was purged with helium gas according to the manufacturer’s 
recommendations. 
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2.5.3 Angle of repose 
Angles of repose were measured in triplicate according to the United States 
Pharmacopoeia (USP) method (USP General Chapter, 2015a). Images of the powder 
mounds were taken using a digital camera and were analyzed using the ImageJ software 
(Wayne Rasband, Research Services Branch, National Institute of Mental Health, 
Bethesda, MD, USA). 
2.5.4 Bulk and tapped density  
The bulk density (ρB) and tapped density (ρT) calculations were performed using a 
tapped density tester (Agilent Technologies, Santa Clara, CA, USA) for a small mass of 
powder using a modified USP method (USP General Chapter, 2015b). In this modified 
method, a 10 mL graduated cylinder fitted with a molded adapter substituted the 100 mL 
graduated cylinder in the tapped density tester. The compressibility index (CI) and 
Hausner ratio (HR) calculations were performed according to the following formulas 
(USP General Chapter, 2015a): 
 !" = 100 ×  !!!!!!!   (3) 
 !" =  !!!! (4) 
2.6 In vitro aerodynamic performance testing 
For the in vitro aerodynamic performance testing, the DPI device was a high-
resistance monodose RS01, a gift from Plastiape S.p.a. (Osnago, Italy). Vcaps No. 3 
hydroxypropyl methylcellulose (HPMC) capsules were provided by Capsugel Inc. 
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(Morristwon, New Jersey, USA). The in vitro aerodynamic performance of carrier-free, 
high-dose DPI formulations were assessed using the Next Generation Impactor (NGI) 
(MSP Corporation, MN, USA) attached sequentially to a Whatman® HEPA filter (GE 
Healthcare Bio-Sciences, Pittsburg, PA, USA), a volumetric digital flow meter (TSI 4000 
Series, TSI Performance Measurement Tools, Shoreview, MN, USA), a two-way 
solenoid valve timer, and a high-capacity vacuum pump (HCP5, Copley Scientific 
Limited, Nottingham, UK).  
For these studies, the DPI device was loaded with an HPMC capsule containing 
10, 25, or 50 mg of IBU5 or 25 mg of IBU10.1, IBU10.2, or IBU20. Capsule filling was 
conducted manually using a micro-spatula and an analytical balance where capsule fill 
weight did not include the capsule shell weight. To minimize the drug burden on patients 
due to high dosage requirement of ibuprofen, it is important to use the largest capsule fill 
weight where the performance is not affected by it. No. 3 capsules can be filled with a 
maximum capsule fill weight of 50 mg. 10 and 25 mg capsule fill weights were selected 
to represent the low- and mid- values for the capsule fill weights. Table 4.2 describes the 
formulations for in vitro aerodynamic performance studies with addition of the 
unprocessed IBU as negative control. Before testing, the preseparator was loaded with 15 
mL of ethanol, and the NGI stages were coated with silicon oil via application of 1 % 
(v/v) of silicon oil in hexane. The temperature and relative humidity were measured using 
an SRH77A thermo-hygrometer by Cooper-Atkins Instrument Corporation (Middlefield, 
CT, USA). The in vitro aerodynamic performance of formulations were evaluated at a 
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flow rate of 58.8 L/min creating a 4 kPa pressure drop across the DPI device (Yazdi and 
Smyth, 2015) for 4.08 s for a total volume of 4 L per Chapter 601 of the USP, apparatus 5 
for inhalation powders in triplicate (USP General Chapter, 2015c). The capsule, the 
inhaler base, the mouthpiece, the adapter, the induction port, the preseparator, the stages 
1 – 7, and the micro-orifice collector (MOC) were each washed twice with 5 mL of 
ethanol and their UV-absorbance were analyzed at the wavelength of 265 nm using a 
Tecan® Infinite® 200 PRO multimode microplate reader (Tecan Systems, Inc. San Jose, 
CA, USA).  
Drug mass in each fraction was quantified. Emitted dose percentage (ED) was 
calculated as the percentage of the entire dose depositing downstream from the 
mouthpiece of the DPI where the entire dose is the total recovered drug mass in all the 
fractions. Respirable fraction percentage (RF) was calculated as the percentage of the 
entire dose deposited on stages two through seven plus the MOC. Fine particle fraction 
percentage (FPF) was calculated as the percentage of the emitted dose deposited on the 
stages two through seven plus the MOC. Fine particle (< 5 µm) fraction percentage 
(FPF5µm), fine particle (< 3 µm) fraction percentage (FPF3µm), and fine particle (< 1 
µm) fraction percentage (FPF1µm) corresponded to the percentage of the emitted dose 
predicted to have the aerodynamic diameter below 5, 3, and 1 µm respectively. The 
FPF5µm, FPF3µm, and FPF1µm values were interpolated from a graph with the 
cumulative percentage of the emitted dose deposited downstream from an NGI stage as 
the ordinate and the particle cutoff size of that stage as the abscissa.  
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2.7 PSD analysis by laser light diffraction 
PSDs were determined using a Sympatec Helos equipped with a Cuvette module 
(System-Partikel-Technik GmbH, Clausthal-Zellerfeld, Germany). Data were analyzed 
using the Sympatec WINDOX software. For each measurement, per a previously 
optimized method, about 2 mg of powder was dispersed in 0.5 mL of 0.1% (w/v) sodium 
dodecyl sulfate in water and the sample was sonicated for 5 min. A reference 
measurement was performed on the cell filled with 50 mL of 0.005% (v/v) Tween 20 and 
50 µL of 2.5 N hydrochloric acid in water. After the reference measurement, 50 µL 
aliquots of the sonicated suspension were added to the cell to achieve optical 
concentrations between 10 to 20 % and the total of six measurements were performed on 
each sample. Formulations were analyzed immediately following air-jet milling 
(25IBU10.1, 25IBU10.2) and after 6 months (25IBU10.1**, 25IBU10.2**) stored at RT 
(IBU10.1), or at -80°C (IBU10.2). 
3 Results  
3.1 SEM 
As depicted in Figure 4.1, the samples IBU5, IBU10.1, IBU10.2, and IBU20 
consisted of micronized particles with plate-like morphology as agglomerates of 10 to 30 
µm. There were no morphological differences between the milled IBU batches. 
3.2 XRD 
XRD spectra from the unmilled IBU and the samples IBU5, IBU10.1, IBU10.2, 
and IBU20 overlapped (Figure 4.2) and peaks corresponded closely with the peaks from 
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the solved XRD diffractogram of racemic IBU (McConnell, 1974), which is listed in 
Cambridge Structural Database (refcode: IBPRAC). 
3.3 DSC 
DSC thermograms for the sample IBU20 and unmilled IBU (Figure 4.3) 
possessed endotherms at 77.78°C and 77.18°C corresponding to the melting point of 
IBU. There were no other endotherms, exotherms, or phase transitions in the 
thermograms.  
3.4 FT-IR 
Peaks associated with the FT-IR spectra for the sample IBU20 and unmilled IBU 
overlapped (Figure 4.4). The 1712.43 cm-1 sharp peaks corresponded with the carbonyl 
group of the carboxylic acid functionality of the IBU molecule. The group of peaks 
surrounding 2955.20 cm-1 corresponded with the sp2 carbon-hydrogen bond stretches of 
the aromatic ring superimposed on the carboxylic acid oxygen-hydrogen bond stretch. 
Finally, 779.99 cm-1 corresponds with para substitution on the aromatic ring of IBU. 
3.5 Powder characterization 
Table 4.3 summarizes the powder characterization for the sample IBU20 and unmilled 
IBU. There was a six-fold difference in SSA between the two samples (2.02 vs. 0.36 
m2/g); however, the true density measurements were the same. The calculated CI and HR 
based on the density measurements were as follows: 45.00 vs. 39.19 and 1.82 vs. 1.64. 
According to the USP, calculated CI greater than 25 and HR greater than 1.34 are 
indicative of poor flowability; however, the angle of repose improved from 62.6 ± 2.9° 
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for the unmilled IBU to 37.8 ± 5° for the sample IBU20. IBU was transformed from a 
powder with almost very, very poor flow to one with almost good flow according to 
angle of repose testing (USP General Chapter, 2015a). 
3.6 In vitro aerodynamic performance testing 
Testing was conducted at relative humidity levels between 28 and 51 % and RT of 
23 and 25° C. Formulations 10IBU5, 25IBU5, and 50IBU5 performances were compared 
to evaluate the capsule fill weight effect (Figure 4.5). Formulations 25IBU5, 25IBU10.1, 
25IBU10.2, and IBU20 performances were compared to investigate the batch size effect 
(Figure 4.6). Capsule fill weight and batch size did not significantly affect the 
performance. Formulations 25IBU20, 25IBU20*, 25IBU10.1, 25IBU10.1** 
performances were compared to evaluate the formulation performance effect on aging 
(Figure 4.7). Formulations 25IBU10.1, 25IBU10.1’, and 25IBU10.1” performances were 
compared to evaluate the storage temperature effect (Figure 4.8). An increased storage 
duration and temperature affected the performance negatively. Finally, formulations 
25IBU10.1, 25IBU10.1**, 25IBU10.2, and 25IBU10.2** performances were compared 
to evaluate the storage temperature effect on aging (Figure 4.9). Decreased storage 
temperature was associated with improved performance. 
3.7 PSD analysis 
The PSDs for formulations 25IBU10.1, 25IBU10.1**, 25IBU10.2, and 
25IBU10.2** are reported in Figure 4.10. The D50 and D90 values for the sample 
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increased at RT after a six-month storage (2.19 & 4.23 µm vs. 3.00 & 13.23 µm). 
However, the D50 and D90 values for the sample did not change at -80°C after a six-month 
storage (2.74 & 7.56 µm vs. 2.43 & 4.77 µm). The appearance of a secondary peak in the 
PSD after a six-month storage at RT was responsible for this increase. 
4 Discussion 
The jet-milled samples possessed a plate-like morphology according to the SEM 
micrographs (Figure 4.1) and were crystalline as determined by XRD (Figure 4.2). The 
crystalline structure corresponded with the conventional phase (phase I) of IBU 
(Dudognon et al., 2008). The DSC thermogram and FT-IR spectrum for sample IBU20, 
representative of all milled samples, corresponded to the thermogram and spectrum for 
the unmilled IBU (Nokhodchi et al., 2015). The melting point drop following air-jet 
milling, from 77.78 to 77.18° C, was due to the smaller particle size of the milled sample 
in comparison with the unmilled sample (Révész, 2005). The true density measurements 
by helium pyncometry matched the literature reported value (Ostrowska et al., 2015).  
Powder flow is critical in pharmaceutical processing including capsule filling for 
DPIs (Shah et al., 2008). Sample IBU20 showed an improved powder flow, signified by a 
smaller angle of repose, in comparison with the unmilled IBU (Table 4.3). However, this 
observation was in contrast with the calculated CI and HR values and the notion that air-
jet milling leads to poor powder flow due an increase in adhesive and cohesive forces 
where Van der Waals forces become greater than gravitational forces (Hickey, 2003). As 
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evident in the SEM micrographs, the milled IBU particles formed agglomerates, which 
likely behaved as granules and resulted in a smaller angle of repose.  
The SSA and the PSD parameters for sample IBU20 indicate formation of 
reversible agglomerates as opposed to irreversible agglomerates. The D10, D50, D90 values 
for sample IBU20 were associated with individual particles, as agglomerates were 
disintegrated upon dispersion before sizing. Moreover, the theoretical particle size (Dtheo 
= 2.88 µm) was calculated based on SSA and ρ according to Equation 5 (Lowell et al., 
2004). The calculated Dtheo value for sample IBU20 corresponded to the measured D50 
value for the PSD, which implies the surface area for individual particles contributed to 
SSA. However, irreversible agglomerates would be associated with a smaller SSA and 
larger Dtheo value in comparison with reversible agglomerates. Moreover, superior in vitro 
aerodynamic performance data (Figures 4.5 – 4.9) may imply that IBU particles form 
loose agglomerates. 
 !!!!" =  !!!" × ! (5) 
As depicted in Figure 4.5, the ED values were about 70 % regardless of the 
capsule fill weight. The RF values decreased slightly; however, the FPF values decreased 
when the capsule fill weight increased from 10 to 50 mg. The observed drops were the 
most significant for the FPF1µm value for formulation 50IBU5 with a relative drop of 25 
% in comparison with formulation 10IBU5. It has been previously shown that the 
monodose RS01 device resistance decreases with the increasing capsule fill weight for 
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the high resistance monodose RS01 device (Yazdi and Smyth, 2015). A decreased device 
resistance is associated with a decreased deagglomeration efficiency at similar flow rates 
(de Boer et al., 2012; Hassoun et al., 2015). The decreased RF and FPF values can be 
explained by the decreased degree of deagglomeration due to the resistance drop. Even 
though the performance was negatively affected by increasing capsule fill weight, the 
decrease is not clinically significant since at least half of the dose per capsule can be 
delivered in practice.  
A closer inspection of the breakdown of the deposition percentage for the 
different capsule fill weights showed an increasing recovery percentage of the dose from 
the capsule walls with a decreasing capsule fill weight; however, the recovered IBU mass 
was about 1 mg across all capsule fill weights. Conversely, significantly larger IBU mass 
was recovered from the inhaler for 50IBU5 in comparison with 10IBU5 (27 vs. 20 %, 14 
vs. 2 mg). Accordingly, similar ED values were achieved for different capsule fill 
weights. Decreased FPF values were due to increased deposition levels in the induction 
port and the preseparator because of reduced deagglomeration efficiency with increasing 
capsule fill weights. 
The RF values for formulations of different samples ranged from 49 to 55 % and 
were not significantly different (Figure 4.6). Except formulation 25IBU10.2, the ED 
value remained at about 70 % for other formulations (25IBU5, 25IBU10.1, 25IBU20); 
however, formulation 25IBU10.2 possessed the highest FPF values at 1, 3, and 5 µm. The 
deposition percentage breakdown showed the highest deposition in the capsule, inhaler 
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base, mouthpiece, and stages four through seven and the lowest deposition in the 
induction port and preseparator for formulation 25IBU10.2. This deposition pattern 
implies that sample IBU10.2 contained the highest percentage of fine particles in 
comparison with the other milled samples. Fine particles adhere to the interior of the 
capsule, inhaler base, and mouthpiece; however, large particles are trapped in the 
induction port and preseparator during in vitro aerodynamic performance testing for DPI 
formulations.  
There was a significant drop in the RF value from 52 to 43 % for the formulation 
25IBU20 analyzed immediately following air-jet milling and after a 21-day storage in a 
desiccator under vacuum at RT (Figure 4.7). Additionally, there was a similar drop in the 
RF value from 49 to 40 % for formulation 25IBU10.1 analyzed immediately following 
air-jet milling and after a six-month storage at the same conditions (Figure 4.9). For both 
formulations, the ED values improved from 72 to 81 %; however, the FPF, FPF5µm, and 
FPF3µm values dramatically dropped by 20 % and the FPF1µm values decreased by 50 
%. Specifically, the deposited IBU mass in the inhaler base and mouthpiece decreased, 
and the deposited IBU mass in the induction port and preseparator increased. This 
observation was attributed to IBU particle size growth and the formation of irreversible 
agglomerates within 21 days. However, there were no further changes from 21 days to six 
months of storage.  
Upon storage at RT, a secondary peak upstream of the primary peak appeared in 
the PSD corresponding with the irreversible aggregates, which did not break apart upon 
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dispersion before sizing (Figure 4.10). As it was previously discussed in the introduction, 
amorphous domains could be created during air-jet milling of crystalline material due to 
high energy input (Ward and Schultz, 1995). Techniques such as DSC and XRD utilized 
in this paper to assess amorphous content did not possess the required resolution to make 
this assessment and detect these domains. Bridges could form between neighboring 
microparticles upon the crystallization of these domains and reversible agglomerates 
transform into irreversible agglomerates (Brodka-Pfeiffer et al., 2003).  
The in vitro aerodynamic performance following a 24-hour purge with helium at 
30° C versus RT yielded similar results, whereas an increased temperature accelerated 
this transformation to under 24 h (Figure 4.8). The in vitro aerodynamic performance 
immediately after air-jet milling and after six months at -80° C for formulation 
25IBU10.2 was compared with the in vitro aerodynamic performance at RT for 
formulation 25IBU10.1 (Figure 4.9). Sample storage at -80° C limited the formation 
extent of irreversible aggregates and preserved the RF value at 51 % following six-month 
storage. The secondary peak, corresponding with the irreversible aggregates, was absent 
in the PSD upon storage at -80° C in comparison with storage at RT (Figure 4.10).  
The in vitro aerodynamic performance data, following storage at RT and -80° C 
(Figures 4.7 & 4.9), suggest the need for a conditioning period immediately after air-jet 
milling and before further processing. The conditioning period could constitute, at least, a 
21-day storage at RT, following which performance would stabilize after an initial drop. 
The performance following this conditioning period is acceptable since it is limited to a 
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20 % relative drop and is superior in comparison with most commercial DPI formulations 
(Donovan, 2015). Alternatively, the conditioning temperature could be reduced down to -
80° C, during which the formation extent of irreversible aggregates is limited. However, 
this conditioning period is associated with an increased cost due to the temperature 
requirements. 
The current study is the first report of in vitro aerodynamic performance data for a 
carrier-free, high-dose formulation of IBU. The RF values were at least about 50 % for 
all formulations immediately after air-jet milling. With a minimum FPF3µm and ED 
values of 55.8 and 72.6 % for formulation 25IBU10.2, 40 % of the dose is predicted to 
reach the deep lung with an aerodynamic diameter below 3 µm. These values are 
significantly larger than most commercial DPI formulations (Donovan, 2015). To achieve 
the estimated maximum 300 mg/day dose requirement for CF via pulmonary delivery, 
based on an approximate maximum 3 g/day oral dose, six capsules with 50 mg capsule 
fill weight are required to be administered every twelve hours assuming RF of 50 %. 
Further experiments are warranted to evaluate other performance considerations (e.g. 
flow rate dependency, 2 kPa pressure drop, etc.) for the carrier-free, high-dose IBU 
formulation in combination with the high-resistance monodose RS01 inhaler. 
5 Conclusion 
The in vitro aerodynamic performances of the carrier-free, high-dose DPI 
formulations of IBU were tested for the first time. The formulations exhibited superior 
performance with predicted lung delivery of at least 40 % of the dose regardless of 
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capsule fill weight, batch size and storage conditions. It is likely that some loose 
crystalline agglomerates in the carrier-free formulation transformed into irreversible 
agglomerates upon aging at RT within one month; however, there were no further 
changes by six months. This transformation is temperature dependent; it occurred within 
24 h at 30° C and did not occur at -80° C during a six-month period. The performance 
was minimally influenced by capsule fill weight and batch size. 
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Figure 4.1: The scanning electron microscopy images of jet-milled ibuprofen batches: (A) 





Figure 4.2: The one-dimensional diffractograms for unmilled ibuprofen (IBU) and 5, 10, 




Figure 4.3: The differential scanning calorimetry thermograms for unmilled ibuprofen 




Figure 4.4: The Fourier transform infrared spectra for unmilled ibuprofen (IBU) and the 




Figure 4.5: The in vitro aerodynamic performance of jet-milled ibuprofen formulations 
with 10, 25, 50 mg capsule fill weight (10IBU5, 25IBU5, 50IBU5) in combination with 
the high-resistance Monodose RS01 at 4 kPa pressure drop (N=3). respirable fraction 
percentage (RF), emitted dose percentage (ED), fine particle fraction percentage (FPF), 
fine particle (< 5 µm) fraction percentage (FPF5µm), fine particle (< 3 µm) fraction 
percentage (FPF3µm), fine particle (< 1 µm) fraction percentage (FPF1µm), mass median 




Figure 4.6: The in vitro aerodynamic performance of jet-milled ibuprofen formulations 
(25IBU5, 25IBU10.1, 25IBU10.2, 25IBU20) from 5, 10, and 20 g batches in combination 
with the high-resistance Monodose RS01 at 4 kPa pressure drop (N=3). respirable 
fraction percentage (RF), emitted dose percentage (ED), fine particle fraction percentage 
(FPF), fine particle (< 5 µm) fraction percentage (FPF5µm), fine particle (< 3 µm) 
fraction percentage (FPF3µm), fine particle (< 1 µm) fraction percentage (FPF1µm), 




Figure 4.7: The in vitro aerodynamic performance of jet-milled ibuprofen formulations 
(25IBU20, 25IBU20*, 25IBU10.1, 25IBU10.1**) after air-jet milling and after 21 days 
(*) or 6 months (**) stored at room temperature in combination with the high-resistance 
Monodose RS01 at 4 kPa pressure drop (N=3). respirable fraction percentage (RF), 
emitted dose percentage (ED), fine particle fraction percentage (FPF), fine particle (< 5 
µm) fraction percentage (FPF5µm), fine particle (< 3 µm) fraction percentage (FPF3µm), 
fine particle (< 1 µm) fraction percentage (FPF1µm), mass median aerodynamic diameter 
(MMAD), geometric standard deviation (GSD). 
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Figure 4.8: The in vitro aerodynamic performance of jet-milled ibuprofen formulations 
(25IBU10, 25IBU10’, 25IBU10.1”) after air-jet milling and after 24 hours outgassing 
with helium at room temperature (’) or 30°C (”) in combination with the high-resistance 
Monodose RS01 at 4 kPa pressure drop (N=3). respirable fraction percentage (RF), 
emitted dose percentage (ED), fine particle fraction percentage (FPF), fine particle (< 5 
µm) fraction percentage (FPF5µm), fine particle (< 3 µm) fraction percentage (FPF3µm), 
fine particle (< 1 µm) fraction percentage (FPF1µm), mass median aerodynamic diameter 
(MMAD), geometric standard deviation (GSD). 
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Figure 4.9: The in vitro aerodynamic performance of jet-milled ibuprofen formulations 
after air-jet milling (25IBU10.1, 25IBU10.2) and after 6 months (25IBU10.1**, 
25IBU10.2**) stored at room temperature (IBU10.1), or at -80°C (IBU10.2) in 
combination with the high-resistance Monodose RS01 at 4 kPa pressure drop (N=3). 
respirable fraction percentage (RF), emitted dose percentage (ED), fine particle fraction 
percentage (FPF), fine particle (< 5 µm) fraction percentage (FPF5µm), fine particle (< 3 
µm) fraction percentage (FPF3µm), fine particle (< 1 µm) fraction percentage (FPF1µm), 
mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD).  
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Figure 4.10: The particle size distributions of formulations after air-jet milling 
(25IBU10.1, 25IBU10.2) and after 6 months (25IBU10.1**, 25IBU10.2**) stored at 
room temperature (IBU10.1), or at -80°C (IBU10.2). 
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Table 4.1: The D10, D50, D90, and span values for 5, 10, and 20 g batches of jet-milled 
ibuprofen (IBU5, IBU10.1, IBU10.2, IBU20). 
Notation Batch (g) D10 (µm) D50 (µm) D90 (µm) Span 
IBU5 5 0.8 1.9 3.6 1.5 
IBU10.1 10 0.9 2.2 4.2 1.5 
IBU10.2 10 1.0 2.7 7.6 2.4 




Table 4.2: Dry powder inhaler capsule fill weights and experimental conditions for 5, 10, 
and 20 g batches of jet-milled ibuprofen (IBU5, IBU10.1, IBU10.2, IBU20) for the in 
vitro aerodynamic performance analysis studies. 
Capsule fill weight 10 mg 25 mg 50 mg 





IBU10.2  25IBU10.2, 25IBU10.2**  
IBU20 - 25IBU20, 25IBU20* - 
*/** Formulations were stored in a desiccator under vacuum for 21 days (*), or 6 months 
(**) at room temperature (IBU10.1, IBU20), or at -80° C (IBU10.2). 
’/” Formulations were purged with helium for 24 h at room temperature (’), or at 30°C 
(”).  
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Table 4.3: Sample characterization for the unmilled ibuprofen (IBU) and the 20 g batch 
of jet-milled ibuprofen (IBU20) 
Sample SSA (m2/g)a ρ (g/cm3)a ρB (g/cm3) ρT (g/cm3) HR CI 
Angle of 
Repose (°)a 
Unmilled IBU 0.36 ± 0.01 1.14 ± 0.00 0.27 0.44 1.64 39.19 62.6 ± 2.9 
IBU20 2.02 ± 0.20 1.15 ± 0.01 0.12 0.21 1.82 45.00 37.8 ± 5.0 
 
a N=3, specific surface area (SSA), bulk density (ρB), tapped density (ρT), true density (ρ), 
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Objective: To crystallize diclofenac (DF) from diclofenac sodium (DFNa), to micronize 
DF and DFNa, and to evaluate in vitro aerodynamic performance of the jet-milled 
formulations 
Material and methods: From the acidic titration of aqueous DFNa, DF crystals were 
formed and were identified using thermal analysis, spectroscopy, and X-ray powder 
diffraction. Following the micronization of the DF and DFNa powders, the recovered 
samples were imaged, and their particle size distributions were evaluated. Samples before 
and after jet millings were characterized, and in vitro aerodynamic performance testing 
was performed on the DF sample before jet milling and the DF and DFNa samples 
following jet milling. 
Results and discussion: Hollow needles of DF were precipitated. With similar particle 
size distributions, the jet-milled DFNa sample from the collection bag, and the DF 
sample from the cyclone were used for further characterization. Despite different 
deposition patterns in the Next Generation Impactor, the DF hollow needles had a 
comparable respirable fraction percentage to the jet-milled DF and DFNa particles. 
However, the jet-milled DF formulation had the best in vitro aerodynamic performance. 
Conclusions: Hollow, crystalline needles of DF were formed and possessed promising 





Diclofenac (DF) is a non-steroidal anti-inflammatory agent (NSAID) indicated for 
analgesia, osteoarthritis, rheumatoid arthritis, migraine, and other inflammatory 
disorders. It has been commonly formulated as its sodium and potassium salts, i.e. 
diclofenac sodium (DFNa) and diclofenac potassium. The DF salts are marketed as 
tablets, capsules, or solutions for oral administration, solutions for intravenous 
administration, solutions for ophthalmic administration, and as creams, gels, patches and 
solutions for topical administration (Lexi-Comp Inc., 2015). 
Despite the availability of NSAIDs as over-the-counter (OTC) medications, there 
are multiple contraindications, black-boxed warnings, and general warnings regarding 
their use (Lexi-Comp Inc., 2015). Gastrointestinal adverse drug reactions (ADRs) such as 
an increased risk of upper gastrointestinal bleeding associated with the use of NSAIDs is 
well documented (Rodriguez and Jick, 1994). Two primary contraindications for the use 
of NSAIDs are the treatment of perioperative pain following coronary artery bypass graft 
surgery and the use in patients with moderate to severe renal impairment (Murray and 
Brater, 1993). Recently, the United States’ Food and Drug Administration (FDA) 
strengthened their warning about the risk of NSAIDs causing heart attacks or stroke 
(Center for Drug Evaluation and Research, 2015). The risk of heart attacks and strokes is 
increased as early as the first few weeks of NSAID use, and risk level is drug-, dose- and 
duration-dependent. Finally, there is an increased risk of heart failure with NSAID use 
(Center for Drug Evaluation and Research, 2015). 
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Delivery via the lung represents a unique opportunity to circumvent the 
prostaglandin (PG) independent mucosal injury associated with the oral administration of 
NSAIDs, as it eliminates the direct GI exposures to these drugs (Islam and Gladki, 2008; 
Matsui et al., 2011). Furthermore, the pulmonary drug delivery route usually decreases 
the dose requirements by ten to twenty fold, especially for drugs acting locally on the 
lung (Labiris and Dolovich, 2003). Similarly to the topical delivery, reducing the 
systemic exposure via pulmonary drug delivery, allows for the minimization of the 
cardiovascular risks as well as the systemic PG-dependent, GI adverse effects associated 
with NSAIDs (Klinge and Sawyer, 2013; Wallace, 2008). Finally, the rapid onset times 
that are seen with pulmonary drug delivery for both local and systemic effects (Boss et 
al., 2012) are ideal for the patients, to whom NSAIDs are prescribed. 
Typically with inhaled powders, such as inhaled corticosteroids and β adrenergic 
agonists, it has been found that the binary blends of micronized drug with a lactose 
carrier system significantly improve their performance (Hickey et al., 2007; Hira et al., 
2010; Steckel and Bolzen, 2004). This type of formulation approach may not be feasible 
for inhaled NSAIDs. Despite the ten to twenty fold total dose reduction facilitated by 
local lung delivery of DF, the required doses will still be in the milligram range, greater 
than the upper limit for common binary dry powder inhaler formulations (Telko and 
Hickey, 2005). An example of a carrier-free inhaled product is the Tobi® PodhalerTM, 
containing low-density spray dried particles, which are highly engineered (Novartis, 
2013; Wilson et al., 2013). Particle engineering is the primary technique for improving 
	 131	
the aerosol performance of carrier-free dry powder inhaler (DPI) formulations, through 
the reduction of aerodynamic diameter. Equation 1 describes the relationship between the 
aerodynamic diameter (Dae), the diameter of equivalent volume sphere (Deq), the particle 
density (ρp), the unit density (ρo), and the dynamic shape factor (χ) (Telko and Hickey, 
2005).  
 !!" =  !!"  !!!! ! (Equation 1)  
Developed and patented by Nektar Therapeutics, PulmoSphere® particles are 
highly porous spherical particles with a geometric particle size of less than 5 µm. These 
particles, developed by spray-drying, are characterized by an aerodynamic particle size 
that is much lower than their geometric size, due to their low particle density (Vehring, 
2008). DPI formulations were shown to possess a high lung deposition in patients, as 
measured by gamma scintigraphy (Newhouse et al., 2003). The Tobramycin 
PulmoSphere formulation was approved by the FDA in 2013, for the use with the 
Podhaler inhaler (Novartis, 2013). Additionally, a ciprofloxacin PulmoSphere 
formulation is in Phase III clinical trials under development by Bayer Schering Pharma 
AG and Novartis Pharmaceutical Corp. for use in non-cystic fibrosis bronchiectasis 
(Wilson et al., 2013).  
Another potential particle property that could be utilized to improve the lung 
deposition is particle shape. As shown in Equation 1, needle shaped particles, where the χ 
value is greater than one (Hinds, 2012), possess smaller aerodynamic diameters in 
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comparison with particles of similar mass. However, they are associated with a poor flow 
and further formulation strategies such as a loose aggregate formation are needed to 
improve manufacturability (Ikegami et al., 2003).  
In this study, we attempt to combine the benefits of hollow, low-density particles, 
with the advantages of needle-shaped particles, for the development of a high dose, 
carrier free formulation of DF. Our research hypothesis is that hollow, needle particles of 
DF, with a high aspect ratio, would have a comparable in vitro aerodynamic performance 
to micronized particles of DF and DFNa. This research investigated the particle 
morphology of DF in the forms of DF free acid and DFNa salt, as a carrier-free dry 
powder inhaler formulation for lung delivery. DF was prepared from DFNa utilizing the 
pH-dependent aqueous solubility of DF. Micronized formulations were produced via the 
jet milling of DF and DFNa, and their in vitro aerodynamic performances were evaluated 
using a Next Generation Impactor (NGI). 
2 Materials and Methods 
2.1 Formation of DF free acid from DFNa 
For DF free acid formation experiments, hydrochloric acid (HCl) was purchased 
from Fisher Scientific (Pittsburgh, PA, USA) and the house dH2O was used for preparing 
the solutions. A solution of 5.376 g of DFNa (Letco Medical, Decatur, Alabama, USA) 
was prepared in 1 L dH2O to get a 0.5 % (w/v) concentration of DF in water. Using a 
burette, 2.5 N aqueous HCl was added to the DFNa solution dropwise, and the solution 
pH was obtained using an Accumet® Basic AB/15+ (Fisher Scientific, Pittsburgh, PA, 
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USA). Titration of the conjugate base of DF was continued until the solution reached a 
pH of 2.0. The precipitate was vacuum filtered and was dried overnight in a 40°C oven. 
2.2 Jet milling of DF and DFNa 
Model 00 Jet-O-MizerTM (also known as Aljet mill, Fluid Energy, Telford, PA, 
USA) was used to micronize DF and DFNa. Aljet mill was configured according to the 
schematic in Figure 5.1. Jet milling parameters were optimized in unpublished work and 
were previously disclosed in a patent application pertaining to carrier-free high-dose 
formulations of non-steroidal anti-inflammatory agents. The jet-milling parameters are as 
followed: the feed pressure of 65 psi, the grind pressure of 75 psi, the feed rate of 1 
g/min, and the batch size of 5 g. Jet-milled powder samples were collected in scintillation 
vials and were stored in a desiccator under vacuum from different sections of the jet mill 
(Figure 5.1) including: the tube after grinding chamber (bfC), the cyclone (C), the 
collection vessel adapter (D), the collection bag adapter (E), the collection vessel (G), and 
the collection bag (H). Following powder collection and weighing of scintillation vials 
with known tare weights, total yield, and individual recovery percentages were 
calculated. Temperature and relative humidity were measured using a SRH77A thermo-
hygrometer by Cooper-Atkins Instrument Corporation (Middlefield, CT, USA).  
2.3 Scanning Electron Microscopy (SEM) 
Samples were mounted on standard aluminum SEM stubs, were sputter coated 
with 15 nm platinum/palladium (Pt/Pd) using a Cressington sputter coater 208 HR 
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(Cressington Scientific Instruments Ltd., Watford, UK) and were imaged using a Zeiss 
Supra 40VP SEM (Carl Zeiss Microscopy GmbH, Jena, Germany). 
2.4 Particle size distribution (PSD) analysis by Laser light diffraction 
PSDs of DF and DFNa samples from the bfC, C, D, E, G, and H segments were 
analyzed before and after jet milling using a Sympatec HELOS, equipped with a 
CUVETTE module (System-Partikel-Technik GmbH, Clausthal-Zellerfeld, Germany). 
Tween 20 and Sodium Lauryl Sulfate (SLS) were purchased from Fisher Scientific 
(Fisher Scientific, Pittsburgh, PA, USA), and house dH2O was used for preparing 
solutions. For DF, about 2 mg of DF was dispersed in 0.5 mL of 0.1 % (w/v) SLS in 
water and the sample was sonicated for 5 minutes. Reference measurement was done on 
acidified 50 mL of 0.005 % (v/v) Tween 20 in water with 50 µL of 2.5 N HCl in water. 
For DFNa, about 2 mg of DFNa was dispersed in 0.5 mL of 0.1 % (v/v) Span 85 in light 
mineral oil and the dispersion was sonicated for 5 minutes. A reference measurement was 
done in 0.1 % (v/v) Span 85 in light mineral oil. After a reference measurement, aliquots 
of 50 µL of sonicated suspension were added to achieve optical concentrations of 10 – 20 
% for a total of six measurements.  
Furthermore, D10, D50, and D90 values were defined as 10 %, 50 %, and 90 % of 
the particle size below the respective values. Span was calculated according to the 
following formula: 
 !"#$ = !!"!!!"!!"  (Equation 2) 
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Normalized cumulative PSDs were composed of yield-normalized distributions, 
where they were depicted as stacked bar charts. D90, D50, and D10 values for normalized 
cumulative PSDs were calculated by approximating particle sizes associated with 90 %, 
50 %, and 10 % area of the stacked bar chart. The approximated values from this method 
were validated with the D90, the D50, and the D10 values for a single distribution by the 
Sympatec software.  
2.5 Thermal analysis 
Thermograms were obtained using an Auto Q20 (TA Instruments-Waters LLC, 
New Castle, DE, USA) differential scanning calorimeter (DSC) controlled by TA 
Advantage Software (TA Instruments-Waters LLC, New Castle, DE, USA) and equipped 
with a RCS40 (TA Instruments-Waters LLC, New Castle, DE, USA) refrigerated cooling 
system with nitrogen purge of 50 mL/min. About 4 mg of samples were loaded in 
standard DSC pans (DSC Consumables Inc., Austin, MN, USA) and were crimped using 
a Tzero sample press (TA Instruments-Waters LLC, New Castle, DE, USA). Samples 
were heated at the rate of 10°C/min from 30°C to 300°C. 
2.6 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectra were obtained using a NicoletTM iSTM50 FT-IR Spectrometer 
(Thermo Fisher Scientific Inc., Madison, WI, USA) equipped with a germanium 




2.7 X-Ray Powder Diffraction (XRD) 
Two-dimensional X-Ray diffractograms of DF and DFNa before jet milling were 
obtained using an automatic R-Axis Spider (Rigaku Corporation, Tokyo, Japan), an X-
ray single crystal diffractometer controlled by RINT Rapid software with the target 
radiation of Copper at 40 KV voltage and 40mA current. Samples for analysis were 
suspended in light mineral oil and were loaded on loops epoxied to conventional 
goniometer bases. Additionally, a background X-Ray diffractogram of light mineral oil 
loaded on a loop was subtracted from the samples’ diffractograms, one-dimensional 2θ 
diffractograms were generated, and .txt files were saved using 2DP Software (Ragaku 
Corporation, Tokyo, Japan). To analyze the one-dimensional diffractograms using Jade 
(Ragaku Corporation, Tokyo, Japan), .raw files were generated from .txt files using 
ConvX.exe (Mark Bowden, Industrial Research Ltd., Lower Hutt, New Zealand). 
2.8 Powder Characterization 
2.8.1 Brunauer-Emmett-Teller (BET) specific surface area measurements 
Specific surface areas were evaluated via a single-point BET method using a 
Monosorb® surface area analyzer (Quantrachrome Instruments; FL, USA) following 24 
hours outgassing with helium at room temperature before each measurement in 
triplicates. Samples weighed at least 50 mg for the jet-milled powders depending on 
availability and 500 mg for the stock samples. 
 !"#$!"!# !"#$%&' !"#! = !"#$%&' !"#!!"##  (Equation 3) 
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2.8.2 Helium pycnometry 
True densities were measured using a MVP-D160-E multipycnometer 
(Quantrachrome Instruments; FL, USA). For density measurements, the micro cell and 
the micro cell adapter were used, and samples weighed at least 0.1 g for jet-milled 
powders depending on availability and at least 0.6 g for the stocks samples.  
2.8.3 Angle of repose 
The angle of repose measurements were done triplicate according to the United 
States Pharmacopoeia (USP) method (USP  Chapter <1174>, 2014). Images of the 
powder mounds were taken using a digital camera and were analyzed using the ImageJ 
software (Wayne Rasband, Research Services Branch, National Institute of Mental 
Health, Bethesda, MD, USA). 
2.8.4 Bulk and tapped density measurements 
The tapped density (ρT) calculations were performed using a tapped density tester 
(Agilent Technologies, Santa Clara, CA, USA) with a modified method from the USP 
(USP  Chapter <1174>, 2014) for a small mass of powder. In this modified method, a 10 
mL graduated cylinder fitted with a molded adapter substituted the 100 mL graduated 
cylinder for the calculations of the bulk density (ρB) and the use in the tapped density 
tester. The compressibility index (CI) and the Hausner ratio (HR) calculations were 
performed according to the following formulas: 
 !" = 100 ×  !!!!!!!   (Equation 4) 
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 !" =  !!!! (Equation 5) 
2.8.5 Karl-Fischer moisture analysis 
The Moisture content of stock powder and jet-milled powders were measured in 
triplicates using a Photovolt AquatestTM 2010a Moisture Analyser (a.k.a. The CSC 
Aquapal III, CSC Scientific Inc., Fairfax, VA, USA). Powder moisture contents were 
calculated by subtracting the moisture content in 1 mL of anhydrous methanol (Fisher 
Scientific, Pittsburgh, PA, USA) from the moisture content reading from 5 mg powder 
dissolved in 1 mL of anhydrous methanol. 
2.9 Quantitative sample analysis by ultraviolet-visible spectroscopy 
Ultraviolet absorbance was measured using a Tecan® Infinite® 200 PRO 
multimode microplate reader (Tecan Systems, Inc. San Jose, CA, USA) using either a 
cuvette or Costar® Corning® 96-well UV-transparent plate. Ultraviolet-visible absorbance 
scans were performed at wavelengths of 230 – 1000 nm at the resolution of 2 nm. 
Additionally, absorbance scans were performed at similar ranges for an ethanol blank, 
and absorbance differences were plotted against the wavelength and in the Microsoft 
Excel®. Standard concentration curves were prepared for DF and DFNa. Wavelength 
with maximum absorbance was used for such measurements. Regression lines were 
forced through zero, and the R2 values were evaluated.  
2.10 In vitro aerodynamic performance testing 
For the in vitro aerodynamic performance testing, the dry powder inhaler device 
was a high resistance monodose RS01, a generous gift from Plastiape S.p.a., (Osnago, 
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Italy). Vcaps No. 3 HPMC capsules were generous donations from Capsugel Inc. 
(Morristwon, New Jersey, USA). In vitro aerodynamic performance of jet-milled powder 
was assessed using the NGI (MSP Corporation, MN, USA) attached sequentially to a 
Whatman® HEPA filter (GE Healthcare Bio-Sciences, Pittsburg, PA, USA), a volumetric 
digital flow meter (TSI 4000 Series, TSI Performance Measurement Tools, Shoreview, 
MN, USA), a home-built two-way solenoid valve timer box, and a high capacity vacuum 
pump (HCP5, Copley Scientific Limited, Nottingham, UK). For these studies, a high-
resistance Monodose RS01 dry powder inhaler device was loaded with an HPMC capsule 
containing 10 mg of micronized powder. Prior to impactions, the pre-separator was 
loaded with 15 mL of ethanol and the NGI stages were coated with 5 mL of 1 % (v/v) of 
silicon oil in hexane and a silicon oil coat was formed on the stages with hexane 
evaporation. Furthermore, the device resistance was calculated using a dosage unit 
sampling apparatus according to an abbreviated Apparatus B from USP Chapter 601 
(Yazdi and Smyth, 2015) and based on the calculated device resistance, flow rate creating 
a 4 KPa pressure drop across the dry powder inhaler was calculated. Temperature and 
relative humidity were measured using an SRH77A thermo-hygrometer by Cooper-
Atkins Instrument Corporation (Middlefield, CT, USA). In vitro aerodynamic 
performance of carrier free formulations were evaluated at the calculated flow rate for a 
total volume of 4 L per USP Chapter 601, Apparatus 5 for Inhalation Powders in 
triplicates (USP General Chapter <601>, 2009). The dry powder inhaler capsule, the 
inhaler base, the mouthpiece, and the adapter were each washed twice with 5 mL of 
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ethanol, and the 10 mL washes from each were stored in 15 mL centrifuge tubes for 
quantitative sample analysis. Accordingly, the induction port, the stages 1 – 7, and the 
micro-orifice collector (MOC) were each washed twice with 5 mL of ethanol and the 10 
mL washes were collected as described. Finally, the pre-separator was washed with 10 
mL of ethanol, and a total of 25 mL wash was collected.  
Following the quantification of the drug mass in each fraction, the emitted dose 
percentage (ED%) is defined as the percentage of the entire dose depositing downstream 
from the mouthpiece of the dry powder inhaler where the entire dose is the total 
recovered drug mass in all the fractions. The respirable fraction percentage (RF%) is 
defined as the percentage of the entire dose deposited on stages two through seven plus 
the MOC. The fine particle fraction percentage (FPF%) is defined as the percentage of 
the emitted dose deposited on the stages two through seven plus the MOC. Fine particle 
fraction (< 5 µm) percentage (FPF5µm %), fine particle fraction (< 3 µm) percentage 
(FPF3µm %), and fine particle fraction (< 1 µm) percentage (FPF1µm %) are calculated 
from the cumulative % of the emitted dose deposited downstream of the NGI stage versus 
the particle cutoff size of the stage graph and correspond to the percentage of the emitted 
dose predicted to have the aerodynamic diameter below 5, 3, and 1 µm respectively.  
	 141	
3 Results  
3.1 Formation of DF free acid from DFNa 
With the addition of less than 1 mL of 2.5 N HCl to the aqueous solution of 
DFNa, a white precipitate of DF was formed. Vacuum filtration and overnight drying in 
the oven yielded a soft cake of white powder. Physicochemical characterization 
confirmed the presence of the DF free acid.  
3.2 Jet milling of DF and DFNa 
Jet milling was conducted at relative humidity levels between 48-55 % and 
temperatures of around 24°C. Following the jet milling of 5g batches, recovery 
percentages from various sections of the jet mill was determined and are shown in Table 
5.1. There was a 70.6% total recovery associated with DFNa and a 63.6% total recovery 
associated with DF, with the majority of particles deposited in the primary cyclone. 
When comparing DF and DFNa deposition on the different components of the jet mill, 
there were noticeable differences in the percentage recovery from the cyclone, the 
collection vessel, and the collection bag. 
3.3 Scanning Electron Microscopy (SEM) 
Un-micronized DFNa was composed of relatively irregularly shaped particles 
with surface adhered fine particles. Precipitated DF particles were hollow needles with 
smooth surfaces and cross-sections below 5µm, thicknesses of 0.5 µm and an average 
length of 20 µm. The Jet-milled DFNa and DF particles were more similar concerning 
their PSD, as they both were composed of fine particles no larger than 3µm. However, 
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the jet-milled DF particles had a smoother surface than the jet-milled DFNa particles (5. 
3).  
3.4 PSD analysis 
Powders collected from different sections of the jet mill were associated with 
different PSD (Figure 5.3). In 5. 2, D10, D50, D90, and span values are compared for: the 
normalized cumulative particle size distribution of the jet-milled DFNa versus DF, the 
stock DFNa versus DF, as well as the collection bag fraction of jet-milled DFNa versus 
the cyclone fraction of jet-milled DF. The D50 and the span (2.36 µm and 1.41) associated 
with the cumulative particle size distribution for the jet-milled DF were smaller than the 
D50 and the span (3.25 µm and 1.61) for the jet-milled DFNa (Figure 5.4). Due to the 
comparable median particle size for the collection bag fraction from the jet milling of 
DFNa, and the cyclone fraction from the jet milling of DF (2.72 µm vs. 2.61 µm), these 
fractions were chosen for further characterization and in vitro performance analysis, and 
will be referred as jet-milled DFNa and jet-milled DF hereinafter.  
3.5 Thermal analysis 
DSC thermograms of the DFNa and the jet-milled DFNa powders (Figure 5.5) 
possessed two endotherms at 286.66°C and 293.88°C. DSC thermograms of the DF and 
the jet-milled DF powder possess a single endotherm at 181.73°C, corresponding to the 





Peaks associated with the FT-IR spectra of DF and jet-milled DF, as well as 
DFNa and jet-milled DFNa, overlapped. In the DFNa spectrum, the 1557.57 cm-1 and the 
1574.88 cm-1 peaks were associated with the carboxylate group stretching; however, the 
1690.81 cm-1 peak in the DF spectrum was associated with a carboxylic acid stretching. 
Furthermore, the DF spectrum contained a 938.39 cm-1 peak corresponding to the O – H 
bending and the ~3320 cm-1 peak associated with the O – H stretching, both absent in 
DFNa spectrum (Figure 5.6).  
3.7 XRD  
Background subtracted X-ray diffractograms for DF and DFNa were associated 
with different peaks and did not overlap.  
3.8 Powder characterization 
Table 5.3 summarizes the bulk, the tapped, and the true density as well as the 
BET SSA, the angle of repose, and the moisture content determined by Karl-Fischer 
titration. Following jet milling, HR and CI calculations of flow showed no significant 
changes in flow for DF (1.88 and 46.67 vs. 2.08 and 51.85); however, they showed 
improved flow from very, very poor to fair flow for DFNa (1.83 and 45.24 vs. 1.22 and 
18.18). The angle of repose improved from 48.7 ± 5.5 to 26.3 ± 1.7 following jet milling 
for DFNa, improving the flow property of the powder from poor to excellent according to 
the USP. On the other hand, the angle of repose remained good according to the USP 
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classification (34.5 ± 2.3 vs. 31.2 ± 1.2) following jet milling for DF (USP  Chapter 
<1174>, 2014).  
3.9 In vitro aerodynamic performance testing 
Device resistance calculations were performed previously (Yazdi and Smyth, 
2015) on a high-resistance Monodose RS01 dry powder inhaler for the device alone, the 
device loaded with an empty capsule and 10 mg powder mass and device resistances 
were 0.0393, 0.0348, 0.0347 kPa0.5x min/L. The resistance of 0.034 kPa0.5x min/L was 
used to calculate the flow rate of 58.8 L/min that creates a 4 KPa pressure drop. Duration 
of 4.08 s at the flow rate of 58.8 L/min corresponded to 4 L air required per USP for the 
in vitro testing of formulations and inhalers. In vitro aerodynamic performance NGI 
testing was conducted at relative humidity and temperature of 52% and 24°C for jet-
milled DFNa; 41% and 23.7°C for jet-milled DF; and 40% and 24°C for DF. The 
quantitative sample analysis of DF and DFNa were performed at the maximum UV 
absorbance of 282 nm for DFNa and the maximum UV absorbance of 278 nm for DF. 
Percent depositions of the total dose for the different stages of the NGI are shown in 




In the current study, DF free acid was precipitated due to its pH-dependent 
solubility from an aqueous solution of DFNa according to the following formulas: 
 !"#$%&'()# !"#$%& → !"#$%&'()#!(!")+  !"! (Equation 6) 
 !"# →  !! +  !"! (Equation 7) 
 !"#$%&'()#! !" +  !!  → !"#$%&'()#(!) (Equation 8) 
SEM revealed the tubular (i.e. hollow acicular, hollow needle) crystal habit of DF 
free acid. Previously, Beck et al. employed a similar technique to prepare the free acid of 
DF; however, following precipitation, DF was recrystallized from a 1:1 ethanol/water 
solution (Beck et al., 2008). To the best of our knowledge, the current study is the first 
report on DF crystals with hollow needle morphology and the first report for the 
formation of these crystals using a single solvent system where tubular crystals are 
formed only by changing pH. There are other reports of this crystal habit in the literature 
for other drug substances (Eddleston and Jones, 2010; Ulrich et al., 2013; Xiao et al., 
2005). Eddleston and Jones reported the conditions required for the formation of tubular 
crystal habit for caffeine, carbamazepine, carbamazepine dihydrate and theophylline 
monohydrate. The formation of the cavities is attributed to the diffusion limited 
conditions at the center of the growing needle crystal, “where crystal growth is more 
rapid than the diffusion of molecules to the most rapidly growing face of the crystal” 
(Eddleston and Jones, 2010).  
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The DSC, the FT-IR, and the XRD data confirm the identity of DF free acid. In 
Figure 5.5A, the DSC thermogram of DFNa possesses two endotherms at 286.66°C and 
293.88°C, which correspond to a literature value of 284.3°C. On the other hand, in Figure 
5.5B, the DSC thermogram of DF possesses a single endotherm at 181.73°C with no 
evidence of DFNa endotherm corresponding to the reported melting point of DF (Llinàs 
et al., 2007). In the FT-IR spectrum of DFNa (Figure 5.6A), the 1557.57 cm-1 and the 
1574.88 cm-1 peaks are associated with the carboxylate group stretching; however, the 
1690.81 cm-1 peak in the DF spectrum (Figure 5.6B) was associated with the carboxylic 
acid stretching. Furthermore, DF spectrum is associated with the 938.39 cm-1 peak 
corresponding to the O – H bending and the ~3320 cm-1 peak associated with the O – H 
stretching, a bond present in the free acid, but not the sodium salt, thereby confirming the 
formation of DF free acid from DFNa (Beck et al., 2008; Cabaniss and McVey, 1995). 
Finally, the X-ray diffractogram for DF is compared with the literature, and its identity is 
verified as the free acid (Llinàs et al., 2007).  
Through micronization, DFNa went through a six-fold particle size reduction 
(19.5 to 3.25 µm); however, DF went through an only three-fold particle size reduction 
(6.98 to 2.36 µm). Differences in crystal strength and brittleness led to the varying 
extents of particle size reductions observed for DF and DFNa, despite the similar attrition 
energy used for jet milling (Kubavat et al., 2012; Saleem and Smyth, 2010; Shariare et 
al., 2011). DFNa is an ionic compound with a higher melting point than DF, which is an 
organic compound with a lower melting point. Therefore, DFNa requires a higher energy 
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input to achieve a similar particle size. Comparisons of the PSD results for DFNa and DF 
should be interpreted with caution, considering that the dispersion media for the laser 
diffraction were different due to the water solubility of DFNa compared to the pH-
dependent solubility of DF. Furthermore, the starting PSD was much smaller for DF 
compared to DFNa (Figures 5.3 – 5.4, Table 5.2). Additionally, PSD analysis by laser 
diffraction also has limitations for non-spherical particles. The hollow straws of DF have 
a high aspect ratio, and the assumptions required by the principle of measurement for this 
instrument may not be valid. 
Regarding the characterization of samples (Table 5.3), the jet-milled DF and 
DFNa possessed increased SSA compared with DF and DFNa. The abnormally high SSA 
value of 11.3 ± 0.81 m2/g for the jet-milled DFNa is clearly an overestimation of SSA 
since the jet-milled DF with smaller particle size has an SSA of 2.40 ± 0.21 m2/g. This 
overestimation of SSA for the jet-milled DFNa is due to the possible formation of a 
multilayer adsorbate and its condensation on the jet-milled DFNa particles (Bae et al., 
2010; Zalepugin et al., 2010). Regarding the true densities, the DF density of 1.48 g/cm3 
corresponded to the literature true density for the denser polymorph of DF (Castellari and 
Ottani, 1997). The DFNa density of 1.51 g/cm3 seems to be the first report of the true 
density for DFNa. Higher true densities were calculated for the jet-milled powders; 
however, that can be attributed to the low sample mass, the moisture content, and the 
smaller particle size of the powder. An improved angle of repose, as an indicator for 
improved flow properties of DFNa following jet milling, can be due to the agglomeration 
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and the moisture content of the micronized powder. On the other hand, the similar angle 
of repose for the DF powder following jet milling can be attributed to the small initial 
size of the DF particles (D50 = 6.98 µm) and the presence of agglomerates before jet 
milling. Following jet milling, HR and CI calculations of flow showed worsening flow 
for DF; however, they showed improved flow from very poor to fair flow for DFNa. 
During jet milling, different percent recoveries in the cyclone, the collection 
vessel, and the collection bag can be attributed to the smoother, smaller particles of DF 
compared with DFNa, as the DF particles have a higher degree of adhesion to the surface 
of the cyclone and cohesion together. Different PSDs for the various segments of the jet 
mill indicate that particles distribute differently in jet mills as they do in impactors.  
There were no detectable transformations of DF and DFNa following jet milling 
by FT-IR and DSC. Overlapping peaks associated with the FT-IR spectra of DF and jet-
milled DF as well as DFNa and jet-milled DFNa signify that following jet milling, the 
chemical composition of DF and DFNa were not altered. Finally, the similar DSC 
thermograms for DF, and jet-milled DF, as well as DFNa, and jet-milled DFNa signify 
that there are no detectable polymorphic changes after the jet milling of DF and DFNa.  
As illustrated in Figure 5.7, similar masses of drugs remained in the capsules for 
DF, and jet-milled DF and DFNa. However, there was a significantly larger mass of jet-
milled DFNa deposited in the inhaler base and the mouthpiece compared to DF and jet-
milled DF. These differences are not due to the jet-milled DFNa PSD, as its D50 value is 
between the D50 for the DF powder and the jet-milled DF powder. Such a deposition 
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difference may be due to the higher moisture content of DFNa as shown in Table 5.3. 
Moreover, there were significant differences in the induction port and the pre-separator 
deposition between the three formulations. Smooth surfaces of the jet-milled DF and DF 
needles led to increased adhesion to the NGI surfaces and increased cohesion and the 
agglomeration of particles compared to the rough surface of the jet-milled DFNa 
(Kubavat et al., 2012). Furthermore, the larger particle size of the DF needles compared 
with the jet-milled DF and DFNa may be a contributing factor. Such a difference might 
also be partly due to the drug entrapment in the inhaler base and the mouthpiece for the 
jet-milled DFNa compared to the jet-milled DF. Furthermore, the jet-milled DFNa fines 
that reach the NGI stages have the smallest MMAD followed by the jet-milled DF and 
DF. Particle size reduction through jet milling for DF yielded a formulation with an 
overall better in vitro aerodynamic performance as opposed to the unprocessed DF. 
However, when comparing the RF% for the three formulations, DF and jet-milled DFNa 
have a comparable RF%. Even though jet-milled DF does not have the smallest MMAD, 
it is associated with the largest RF% at 41.7%. The DF hollow needles are remarkable as 
they are relatively long; however, due to being hollow and being needles have a relatively 
small MMAD and comparable RF% to the jet-milled powders. 
The carrier-free formulation of DF with the 3 mg respirable dose (RF% = 30%) 
roughly equals to 10% of the 35 mg mass of commercialized DF currently marketed as 
Zorvolex® (Iroko Pharmaceuticals, LLC, 2013), the estimated theoretical respiratory dose 
requirements. In 2013, DF was approved for the first time as a capsule containing 18 mg 
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or 35 mg of DF free acid under the brand name of Zorvolex with a similar 
pharmacodynamic profile to the higher doses of DF salts. This formulation of DF 
contains submicron particles of DF free acid to improve dissolution rate, which is dry-
milled using the patented SoluMatrixTM technology, developed by iCeutica Pty. Inc. 
Particle size reduction was achieved using multiple grinding bodies with diameters of 1-
15 mm and aggregation was prevented by adding a grinding matrix, which can be 
separated before further processing, or be formulated into final formulation (Dodd et al., 
2014). 
As it was discussed in the introduction, one can reduce the aerodynamic diameter 
by manipulating the dynamic shape factor through needle particle engineering (Ikegami 
et al., 2003) and decreasing the particle density through the creation of porous particles 
(Vehring, 2008). The carrier-free, hollow needle formulation of DF, consisting of 
particles with a high aspect ratio, possesses both the described attributes and was shown 
to have a good MMAD and a comparable RF% to the jet-milled DF and DFNa. The 
delivery of the carrier-free formulation to the lung lowers the total dosage requirement 
and decreases the ADRs associated with the oral delivery of the DF. However, the DF 
formulation needs to be optimized to minimize the RF% variability and the deposition in 
the induction port and pre-separator. 
5 Conclusion 
The DF hollow, crystalline needles were precipitated, characterized, and their in 
vitro aerodynamic performance was compared with the jet-milled DF and DFNa using 
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NGI. The Jet-milled DF and DFNa with similar PSDs had different deposition patterns in 
the NGI. However, the DF hollow needles with a large aspect ratio proved to have a 
comparable RF% to the jet-milled DF and DFNa particles. For a carrier-free, DPI 
formulation, this formulation can reach deep lungs to act locally, or systemically with 
reduced ADRs through decreased total dose requirements. 
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Figure 5.1: Schematic of Aljet mill configuration and setup 
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Figure 5.2: A) Unprocessed diclofenac sodium, B) Unprocessed diclofenac, C) Jet milled 




Figure 5.3: Particle size distributions of (A) diclofenac sodium (DFNa) and (B) 
diclofenac (DF) samples from different sections of Jet mill including: tube after grinding 
chamber (bfC), cyclone (C), collection vessel adapter (D), collection bag adapter (E), 




Figure 5.4: Yield normalized cumulative particle size distribution of (A) diclofenac 
sodium and (B) diclofenac from different sections of Jet mill including: tube after 
grinding chamber (bfC), cyclone (C), collection vessel adapter (D), collection bag adapter 




Figure 5.5: DSC thermograms of unprocessed and jet-milled (A) diclofenac sodium 




Figure 5.6: FT-IR spectra associated with unprocessed and jet-milled (A) diclofenac 




Figure 5.7: In-vitro aerodynamic performance of carrier-free formulations of 10 mg 
diclofenac (DF), jet-milled DF and jet-milled diclofenac sodium (DFNa) at 4 KPa 
pressure drop across high-resistance Monodose RS01 (N=3)  
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Table 5.1: % recovery from different sections of the jet mill including: tube after grinding 
chamber (bfC), cyclone (C), collection vessel adapter (D), collection bag adapter (E), 
collection vessel (G), and collection bag (H) for 5 g batches of (A) diclofenac sodium and 
(B) diclofenac  
 bfC C D E G H 
Diclofenac sodium 8.7 23.9 11.5 0.8 11.1 14.6 




Table 5.2: D10, D50, D90, and span associated with relevant samples of diclofenac sodium 
(DFNa) vs. diclofenac (DF)  
 DFNa vs. DF D10 (µm) D50 (µm) D90 (µm) Span 
Normalized cumulative particle size 
distribution of jet-milled DFNa vs. DF 
DFNa 1.29 3.25 6.53 1.61 
DF 1.16 2.36 4.48 1.41 
Stock DFNa vs. DF 
DFNa 2.02 19.5 42.69 2.08 
DF 2.00 6.98 17.34 2.20 
Collection bag from jet-milled DFNa vs. 
cyclone from jet-milled DF 
Jet milled DFNa 1.06 2.72 5.52 1.64 




Table 5.3: Summary table of Powder characterization 
Samples SSA (m2/g)* 
Moisture 
Content (%)* 
ρ (g/cm3) * ρB (g/cm3) ρT (g/cm3) HR CI 
Angle of 
Repose (°)* 
DF 1.73 ± 0.17 0.78 ± 0.18 1.48 ± 0.01 0.16 0.30 1.88 46.67 34.5 ± 2.3 
Jet milled DF 2.40 ± 0.21 0.45 ± 0.10 1.53 ± 0.02 0.12 0.26 2.08 51.85 31.2 ± 1.2 
DFNa 1.37 ± 0.20 1.88 ± 0.20 1.51 ± 0.00 0.38 0.69 1.83 45.24 48.7 ± 5.5 
Jet milled DFNa 11.3 ± 0.81 2.99 ± 0.10 1.68 ± 0.04 0.17 0.20 1.22 18.18 26.3 ± 1.7 
*N=3, Specific Surface Area (SSA), Bulk density (ρB), Tapped density (ρT), True density 




Table 5.4: Summary table of parameters for 10 mg diclofenac (DF), jet-milled DF 
and jet-milled diclofenac sodium (DFNa) carrier-free formulation in vitro 
aerodynamic performance at 4 kPa pressure drop across high-resistance Monodose 
RS01. 
 
 FORMULATION RF % ED % FPF% FPF5µm% FPF3µm % FPF1µm % MMAD GSD 
Jet-milled DFNa 32.9 ± 1.0 43.6 ± 0.8 75.6 ± 3.3 75.9 ± 3.3 72.0 ± 3.8 34.0 ± 3.0 1.9 ± 0.1 2.0 ± 0.0 
Jet-milled DF 41.7 ± 3.5 68.9 ± 2.9 60.4 ± 2.8 60.8 ± 2.8 43.0 ± 1.5 8.6 ± 0.3 3.1 ± 0.1 2.1 ± 0.0 
DF 30.3 ± 5.1 80.3 ± 3.5 37.7 ± 5.6 38.4 ± 5.7 22.5 ± 1.9 3.9 ± 0.6 4.2 ± 0.1 2.2 ± 0.1 
N=3, respirable fraction percentage (RF%), emitted dose percentage (ED%), particle 
fraction percentage (FPF%), fine particle fraction (< 5 µm) percentage (FPF5µm %), fine 
particle fraction (< 3 µm) percentage (FPF3µm %), fine particle fraction (< 1 µm) 
percentage (FPF1µm %), mass median aerodynamic diameter (MMAD), geometric 
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